Document:

Execution
Copy

 

SHARE
EXCHANGE AGREEMENT

 

THIS
AGREEMENT dated as of the 24th day of July, 2017 (the “Effective Date”).

 

A
M O N G :

BRIACELL
THERAPEUTICS CORP., a corporation existing under the laws of the State of Delaware

 

(hereinafter
called the “Acquiror”)

 

OF
THE FIRST PART

 

-
and -

 

BRIACELL
THERAPEUTICS CORP., a corporation existing under the laws of the Province of British Columbia

(hereinafter
called “BriaCell”)

 

OF
THE SECOND PART

 

-
and -

 

SAPIENTIA
PHARMACEUTICALS, INC., a corporation existing under the laws of the State of Delaware

(hereinafter
called “Sapientia”)

 

OF
THE THIRD PART

 

-
and -

 

THE
INDIVIDUALS SET OUT IN EXHIBIT “A” HERETO

(hereinafter
collectively called the “Sapientia Shareholders”)

 

OF
THE FOURTH PART

RECITALS

 

	A.	BriaCell
    is a publicly traded biotechnology company listed on the TSX Venture Exchange (“Exchange”).
	 	 
	B.	The
    Acquiror is a wholly-owned subsidiary of BriaCell.
	 	 
	C.	Sapientia
    is a privately held biotechnology company organized under the laws of the State of Delaware.

 

    	 	 	 

    	 	-2-	 

    

 

	D.	The
    Sapientia Shareholders are collectively the legal and beneficial owners of all of the issued and outstanding common shares
    in the capital of Sapientia (the “Sapientia Shares”).
	 	 
	E.	The
    boards of directors of the Acquiror, BriaCell and Sapientia have determined that it is in the best interests of their respective
    corporations and their respective shareholders that the corporations effect the transactions contemplated by this Agreement
    subject to and on the terms and conditions set forth herein.
	 	 
	F.	The
    Shareholders desire to sell the Sapientia Shares and the Acquiror desires to acquire such Sapientia Shares in consideration
    for the issuance to the Sapientia Shareholders pro rata an aggregate of 2,500,002 common shares in the capital
    of BriaCell (the “BriaCell Payment Shares”), all as more particularly described herein and upon the terms
    and conditions hereinafter set forth.
	 	 
	G.	BriaCell
    and Sapientia intend that the transfer of the Sapientia Shares and BriaCell Payment Shares be accomplished on a tax-free basis
    pursuant to the provisions of Section 368(a)(1)(B) of the Internal Revenue Code of 1986.

 

NOW
THEREFORE THIS AGREEMENT WITNESSETH THAT in consideration of the mutual promises and covenants contained herein, and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby covenant and
agree as follows:

 

ARTICLE
1

INTERPRETATION

 

	1.1	Definitions

 

In
this Agreement and in all amendments hereto the following words, whenever used in this Agreement, unless there is something in
the subject matter or context inconsistent therewith, shall have the following meanings:

 

“Affiliates”
shall include the spouses, parents, children and other members of the families of the Shareholders and any Person controlled
by the Shareholders or any one or more of them.

 

“Agreement”
shall mean this Share Exchange Agreement as amended from time to time.

 

“Claims,
Proceedings or Restrictions” shall mean any claims, legal, administrative or other proceedings, suits, investigations,
complaints, notices of violation or similar process, judgments, injunctions, orders, decrees or directives against, relating to
or directly or indirectly affecting (a) Sapientia, its assets, business or its ability to acquire property or conduct business
in any area, or (b) the officers or directors, agents, employees or consultants of Sapientia, which as to all matters described
in (a) or (b) above if determined adversely to any of the above (or if adopted in the case of proposed governmental restriction),
might individually or in the aggregate, either materially adversely affect the condition (financial or otherwise), operations,
business or prospects of Sapientia, or challenge the validity or propriety of the transactions contemplated by the Agreement,
or the ability of the parties to consummate such transactions in accordance with the terms of the Agreement.

 

“Closing
Date” shall mean the date on which the Closing occurs.

 

“BriaCell
Shares” means common shares in the capital of BriaCell.

 

    	 	 	 

    	 	-3-	 

    

 

“Intellectual
Property” shall mean all patents, trademarks, copyrights, industrial designs, software, trade secrets, know-how, concepts,
information and other intellectual and industrial property.

 

“Financial
Statements” shall mean Sapientia’s financial statements including balance sheet as at December 31, 2016 and the
related statements of income, retained earnings and changes in financial position for the period then ended.

 

“License
Agreement” means the License Agreement dated March 16, 2017 by and between Sapientia Pharmaceuticals, Inc. and Faller
& Williams Technology LLC.

 

“material”
or “materially”, as used in connection with events, contingencies, claims or other matters (or a series
of related such matters) expressly relating in the Agreement to any particular asset of Sapientia or the business of Sapientia
as the case may be, shall include such matters as a reasonably prudent investor would consider important (either, individually,
or when considering the collective effect of all such matters) in deciding whether to purchase such assets, the Sapientia Shares,
or the business of Sapientia on the terms provided herein.

 

“Person”
shall mean any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association,
limited liability company, corporation, institution, public benefit corporation, entity or government (whether federal, provincial,
county, city, municipal or otherwise, including, without limitation, any instrumentality, division, agency, body or department
thereof).

 

“Purchase
Price” shall mean the aggregate consideration to be paid to the Sapientia Shareholders pursuant to Section 2.1 (a).

 

“Securities
Laws” means the securities legislation having application, the regulations and rules thereunder and all administrative
policy statements, instruments, blanket orders, notices, directions and rulings issued or adopted by the applicable securities
regulatory authority, all as amended.

 

“Taxes”
means all taxes and other governmental charges of any kind whatsoever including without limitation, all federal, state, municipal
or other governmental imposed income tax, capital tax, capital gains tax, transfer tax, value-added tax, sales tax, social services,
health, payroll and employment taxes, duty, customs, or import duties and any penalty charges or interest in respect of the forgoing.

 

ARTICLE
2

PURCHASE
AND SALE

 

	2.1	Purchase
    and Sale

 

	 	(a)	Subject
    to the terms and conditions of this Agreement, each of the Sapientia Shareholders agrees to sell all of their ownership interest
    in and to the Sapientia Shares, as described in Schedule 2.1(a), to BriaCell free and clear of all encumbrances and the Acquiror
    agrees to purchase all of the Sapientia Shares.
	 	 	 
	 	(b)	As
    consideration for the Sapientia Shares, BriaCell shall issue pro rata to the Sapientia Shareholders an aggregate of
    2,500,002 BriaCell Payment Shares at the Market Price (as such term is defined in the Exchange Corporate Financial
    Manual) of the BriaCell Shares on the Closing Date. The BriaCell Payment Shares will be issued to the Sapientia Shareholders
    on a pro rata basis based on the number of Sapientia Shares owned by each Sapientia Shareholder immediately prior to
    Closing (as defined herein).

 

    	 	 	 

    	 	-4-	 

    

 

ARTICLE
3

REPRESENTATIONS
AND WARRANTIES RELATING TO SAPIENTIA

 

Sapientia
represents and warrants as of the date of this Agreement and again as of the date of Closing Date to BriaCell as follows:

 

	3.1	Organization,
    Power and Qualification

 

Sapientia
is a corporation duly incorporated, organized and validly subsisting under the laws of the State of Delaware, and has all requisite
corporate power and authority to own or hold under lease its properties and assets and to carry on its business as now conducted.
Sapientia is duly qualified to do business and is in good standing in every jurisdiction in which a failure to so qualify could
have a Material adverse effect upon its properties, assets, financial conditions, results of operation or business prospects.
True and complete copies of the Articles of Incorporation, as amended to date, and the by- laws, as amended to date, of Sapientia
have been furnished to BriaCell. Sapientia has taken all actions required by law, its Articles of Incorporation, or otherwise,
to authorize the execution and delivery of this Agreement. Sapientia has full power, authority, and legal right and has taken
all action required by law, its Articles of Incorporation, and otherwise, to consummate the transactions herein contemplated.

 

	3.2	Capitalization

 

The
authorized capitalization of Sapientia consists of an unlimited number of common stock of which 4,106,653 shares are currently
issued and outstanding and 57,000 common stock options with an exercise price of USD$0.01 which will be converted into common
stock on the Closing Date. All issued and outstanding shares are legally issued, fully paid, and non-assessable and not issued
in violation of preemptive or other rights of any person. All of the currently issued and outstanding stock in the capital of
Sapientia are duly authorized, validly issued and outstanding, as fully paid and non- assessable and have not been issued in violation
of any shareholder rights under applicable law, or of the certificate or articles of incorporation or by-laws or the terms of
any agreement to which Sapientia is a party or by which Sapientia is bound. Sapientia has no outstanding subscriptions, options,
warrants, rights or other agreements granting to any person, firm or corporation any interest in or right to acquire from the
Corporation at any time, or upon the happening of any stated event, any shares in the capital of the Corporation, or any interest
therein

 

	3.3	Subsidiary
    Corporations

 

Sapientia
does not have any predecessor corporation(s) or subsidiaries, and does not own, beneficially or of record, any shares of any other
corporations

 

    	 	 	 

    	 	-5-	 

    

 

	3.4	No
    Violation

 

Neither
the execution and delivery of this Agreement, nor the consummation of the transactions contemplated hereby will constitute a violation
of, or be in conflict with, or result in a cancellation of, or constitute a default under, or create (or cause the acceleration
of the maturity of) any debt, obligation or liability affecting, or result in the creation or imposition of any security interest,
lien, or other encumbrance upon any of the assets owned or used by, or any of the capital stock of, Sapientia under:

 

	 	(a)	any
    term or provision of the certificate or articles of incorporation or by-laws of Sapientia;
	 	 	 
	 	(b)	any
    contract, agreement, indenture, lease or other commitment to which Sapientia or the Sapientia Shareholders is or are party
    or by which Sapientia or the Sapientia Shareholders is or are bound;
	 	 	 
	 	(c)	any
    judgment, decree, order, regulation or rule of any court or governmental authority; or
	 	 	 
	 	(d)	any
    statute or law.

 

No
consent of, or notice to, any federal, state, or local authority, or any private person or entity, is required to be obtained
or given by the Sapientia Shareholders or Sapientia in connection with the execution, delivery or performance of this Agreement
or any other agreement or document to be executed, delivered or performed hereunder by the Sapientia Shareholders or Sapientia.

 

	3.5	Financial
    Statements

 

The
Financial Statements (i) have been prepared in accordance with US GAAP and fairly present the financial condition, assets and
liabilities (whether accrued, absolute, contingent or otherwise) of Sapientia as of the respective dates thereof and the results
of operations and changes in financial position of Sapientia for the periods covered thereby; (ii) Sapientia has no liabilities
with respect to the payment of any federal, state, local or other taxes (including any deficiencies, interest or penalties), except
for taxes accrued but not yet due and payable; and (iii) Sapientia has filed all federal, state or local income and/or franchise
tax returns required to be filed by it from inception to the date hereof and each of such income tax returns reflects the taxes
due for the period covered thereby.

 

	3.6	Absence
    of Certain Changes

 

Since
the date of the Financial Statements, there has not been any Material adverse change in the condition (financial or otherwise)
of the properties, assets, liabilities, results of operation or business prospects of Sapientia.

 

	3.7	Liabilities
    and Obligations

 

Other
than the liabilities and obligations of Sapientia owning to or in favour of Faller & Williams Technology LLC pursuant to the
License Agreement, Sapientia will not at Closing have any liabilities or obligations (direct or indirect, contingent or absolute,
matured or unmatured) of any nature whatsoever, whether arising out of contract, tort, statute or otherwise, other than the liabilities
and obligations.

 

    	 	 	 

    	 	-6-	 

    

 

	3.8	Title
    to and Condition of Assets

 

Sapientia
has good and marketable title to all of its properties, inventory, interests in properties, and assets, real and personal, which
are reflected in the Financial Statements (except properties, inventory, interests in properties, and assets sold or otherwise
disposed of since such date in the ordinary course of business), free and clear of all liens, pledges, charges, or encumbrances
except (a) statutory liens or claims not yet delinquent, (b) such imperfections of title and easements as do not and will not
materially detract from or interfere with the present or proposed use of the properties subject thereto or affected thereby or
otherwise materially impair present business operations on such properties. Sapientia owns, free and clear of any liens, claims,
encumbrances or other restrictions or limitations of any nature whatsoever, any and all products it is currently manufacturing,
including the underlying technology and data, and all intellectual property, procedures, techniques, marketing plans, business
plans, methods of management, or other information utilized in connection with Sapientia’s business. No third party has
any right to, and Sapientia has not received any notice of infringement of or conflict with asserted rights of others with respect
to any product, technology, data, trade secrets, know-how, propriety techniques, trademarks, service marks, trade names, or copyrights
which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would Materially affect
the business, operations, financial condition, income, or business prospects of Sapientia or any material portion of its properties,
assets, or rights.

 

	3.9	Contracts

 

	 	(a)	Except
    as disclosed in Schedule 3.9, there are no contracts, agreements, franchises, license agreements, debt instruments or other
    commitments to which Sapientia is a party or by which it or any of its assets, products, technology, or properties are bound
    other than those incurred in the ordinary course of business which (i) will remain in effect for more than six (6) months
    after the date of this Agreement, and (ii) involves aggregate obligations of at least twenty-five thousand dollars ($25,000);
	 	 	 
	 	(b)	Sapientia
    is not a party to or bound by, and the properties of Sapientia are not subject to any contract, agreement, other commitment
    or instrument; any charter or other corporate restriction; or any judgment, order, writ, injunction, decree, or award which
    materially and adversely affects, the business operations, properties, assets, or financial condition of Sapientia;
	 	 	 
	 	(c)	Except
    as included or described in Schedule 3.9 or reflected in the Financial Statements, Sapientia is not a party to any oral or
    written (i) contract for the employment of any officer or employee which is not terminable on 30 days, or less notice; (ii)
    profit sharing, bonus, deferred compensation, stock option, severance pay, pension benefit or retirement plan; (iii) agreement,
    contract, or indenture relating to the borrowing of money; (iv) guaranty of any obligation, other than one on which Sapientia
    is a primary obligor, for the borrowing of money or otherwise, excluding endorsements made for collection and other guaranties
    of obligations which, in the aggregate do not exceed more than one year or providing for payments in excess of $25,000 in
    the aggregate; (v) agreement with any present or former officer or director of Sapientia; and
	 	 	 
	 	(d)	and
    all such contracts are now in good standing and in full force and effect without amendments thereto and is entitled to all
    benefits thereunder.

 

    	 	 	 

    	 	-7-	 

    

 

	3.10	No
    Default, Violation or Litigation

 

Sapientia
is not in violation of any law, regulation or order of any court or federal, state, municipal or other governmental department,
commission, board, bureau, agency or instrumentality including, without limitation, laws, regulations, orders, restrictions and
compliance schedules applicable to environmental standards and controls, wages and hours, human rights and occupational health
and safety. There are no lawsuits, proceedings, claims or governmental investigations pending or, to the knowledge of the Sapientia
Shareholders, threatened against, or involving, Sapientia or against its property or business. There is no basis known to the
Sapientia Shareholders for any such action which could have a material adverse effect upon the properties, assets, liabilities,
financial condition, results of operations or business prospects of Sapientia or its right to conduct its business as presently
conducted. There are no judgments, consents, decrees, injunctions, or any other judicial or administrative mandates outstanding
against Sapientia.

 

	3.11	Employment,
    Labour and Other Relations

 

Sapientia
is not a party to or is otherwise bound by any contract, agreement or collective bargaining agreement with any labour union or
organization.

 

	3.12	Employee
    Benefits

 

Sapientia
does not have, and never has had, any pension, retirement, savings, disability, medical, dental, health, life (including any individual
life insurance policy to which Sapientia makes premium payments, whether or not Sapientia is the owner, beneficiary or both of
such policy), death benefit, group insurance, profit sharing, deferred compensation, stock option, bonus, incentive, vacation
pay, severance pay, or other employee benefit plan, trust, arrangement, contract, agreement, policy or commitment.

 

	3.13	Patents,
    etc.

 

	 	(a)	Sapientia
    is the sole owner of all rights, title and interest in the Intellectual Property and owns, possesses or has licenses or similar
    rights to utilize all other patents, trademarks, trade names, service marks, franchises, and technology necessary for the
    conduct of its business as presently conducted without any infringement of or conflict with the rights of others. All such
    patents, trademarks, trade names, service marks and franchises, or applications therefore, are disclosed in Schedule 3.13
    and all licenses therefore are disclosed in Schedule 3.13, and Sapientia’s interests therein are similarly disclosed.
	 	 	 
	 	(b)	There
    have never been, and are not currently, any disputes of any kind regarding the Intellectual Property, including, without limitation,
    any disputes regarding infringement, validity or ownership of the intellectual property rights relating to the Intellectual
    Property.
	 	 	 
	 	(c)	No
    person has made any claim or allegation that any of the Intellectual Property or rights relating thereto do not belong to
    Sapientia or that use of the Intellectual Property in any way violate their intellectual property rights, and Sapientia is
    not aware of any claim or potential claim or allegation of this nature or that may impact the ability of BriaCell or its permitted
    assigns to use the Intellectual Property.

 

    	 	 	 

    	 	-8-	 

    

 

	 	(d)	Sapientia
    has the uninterrupted use of the Intellectual Property and to the practice of the methods and inventions as provided for by
    Sapientia.

 

	3.14	Approvals

 

Sapientia
possesses or has applied for all material governmental and other permits, licenses, consents, certificates, orders, authorizations
and approvals (the “Approvals”) to own or hold under lease and operate its property and assets and to carry
on its business as now conducted. Neither the Sapientia Shareholders nor Sapientia has received any notice of proceedings relating
to the revocation or modification of any such Approvals which, singly or in the aggregate, if the subject of an unfavourable ruling
or finding, could materially adversely affect the properties, assets, financial condition, results of operation or business prospects
of Sapientia.

 

	3.15	Transactions
    with Affiliates

 

Sapientia
is not indebted to and has no liabilities or obligations for any amounts or obligations owing to or in favour of the Sapientia
Shareholders or any of their Affiliates.

 

	3.16	Corporate
    Records

 

All
of the minute books and stock record books of Sapientia have been made available to BriaCell and its agents for inspection, are
accurate and correct in all material respects, and contain all of the corporate minutes and stock records of Sapientia from inception
to the date hereof. Such minutes and records for the period from this date to the Closing Date will be made available to BriaCell
on or before Closing. All accounts, books, ledgers, financial and other records of whatsoever kind of Sapientia have been fully,
properly and accurately maintained in all material respects and all transactions of Sapientia that are reflected therein are truly
and accurately reflected in all material respects.

 

	3.17	Confidential
    Information and Employee Intentions

 

To
the best knowledge of the Sapientia Shareholders and Sapientia:

 

	 	(a)	each
    present employee, officer, director, agent or consultant of Sapientia possessing confidential know-how regarding the business
    or assets Sapientia has maintained the confidentiality of said know-how and has not and is not known to intend to use any
    such know-how of Sapientia in a competitive business; and
	 	 	 
	 	(b)	no
    key employee intends to establish or join a business competitive thereto.

 

	3.18	Other
    Material Adverse Information

 

Except
as expressly set forth in this Agreement and the Schedules or in the Financial Statements, Sapientia has no knowledge of any facts
which will or may reasonably be expected to have any Material adverse effect on the value of the business or goodwill of Sapientia,
or upon its prospects or earning power.

 

    	 	 	 

    	 	-9-	 

    

 

	3.19	Disclosure

 

No
representation or warranty of Sapientia made hereunder or in the Schedules or in any certificate, statement or other document
delivered by or on behalf of Sapientia contains any untrue statement of a material fact or omits to state a material fact necessary
in order to make the statements contained herein or therein not misleading. Copies of all documents referred to herein or in the
Schedules have been delivered or made available to BriaCell, are true, correct and complete copies thereof, and include all amendments,
supplements or modifications thereto or waivers thereunder.

 

ARTICLE
4

ADDITIONAL
REPRESENTATIONS AND WARRANTIES OF THE SAPIENTIA 

SHAREHOLDERS

 

The
Sapientia Shareholders severally and not jointly nor jointly and severally, represent and warrant to BriaCell as follows:

 

	4.1	Authorization

 

The
Sapientia Shareholders have full power and authority to execute and deliver this Agreement and all other agreements and documents
to be executed and delivered by the Sapientia Shareholders pursuant hereto, and to consummate the transactions contemplated hereby
and thereby. This Agreement and all other agreements and documents to be executed and delivered by the Sapientia Shareholders
pursuant hereto, constitute the valid and binding agreements of the Sapientia Shareholders, enforceable in accordance with their
respective terms.

 

	4.2	No
    Violation

 

Neither
the execution and delivery of this Agreement by the Sapientia Shareholders, nor of any other agreement or document to be executed
and delivered by the Sapientia Shareholders pursuant hereto, nor the consummation by the Sapientia Shareholders of the transactions
contemplated hereby or thereby will constitute a violation of, or be in conflict with, or result in a cancellation of or constitute
a default under, or create (or cause the acceleration of the maturity of) any debt, obligation or liability affecting the Sapientia
Shares owned by the Sapientia Shareholders pursuant to, or result in the creation or imposition of any security interest, lien,
or other encumbrance upon the Sapientia Shares owned by the Sapientia Shareholders under:

 

	 	(a)	any
    contract, agreement, lease or other commitment to which any Sapientia Shareholder is a party or by which any Sapientia Shareholder
    is bound;
	 	 	 
	 	(b)	any
    judgment, decree, order, regulation or rule of any court or governmental authority; or
	 	 	 
	 	(c)	any
    statute or law.

 

	4.3	Share
    Ownership

 

Each
Sapientia Shareholder is the lawful owner of record and beneficially of the number of Sapientia Shares set forth opposite its
or his name in Schedule 2.1(a) hereto, free and clear of all mortgages, liens, pledges, charges, security interests, encumbrances
or other third party interests of any nature whatsoever, including, without limitation, subscriptions, options, warrants, rights
or other agreements granting to any person, firm or corporation any interest in or right to acquire from any Sapientia Shareholder
at any time, or upon the happening of any stated event, any shares (or interests therein) of the Sapientia Shares owned by any
Sapientia Shareholder.

 

    	 	 	 

    	 	-10-	 

    

 

	4.4	Securities
    Law Representations

 

Each
of the Sapientia Shareholder hereby acknowledges and agrees with BriaCell that:

 

	 	(a)	they
    are acquiring the BriaCell Payment Shares for their own account, for investment purposes only and not with a view to any resale,
    distribution or other disposition of the Securities in violation of the United States securities as contemplated by the provisions
    of Section 2(11) of the Securities Act of 1933 (“US Securities Act”);
	 	 	 
	 	(b)	they
    are each an “accredited investor” as such term is defined in Rule 501(a) of Regulation D under the US Securities
    Act;
	 	 	 
	 	(c)	they
    understand (i) the BriaCell Payment Shares have not been and will not be registered under the US Securities Act or the securities
    laws of any state of the United States; and (ii) the sale contemplated hereby is being made in reliance on an exemption from
    such registration requirements;
	 	 	 
	 	(d)	the
    issuance of the BriaCell Payment Shares in exchange therefor will be made pursuant to appropriate from the formal takeover
    bid and registration and prospectus (or equivalent) exemptions of Canadian Securities Laws;
	 	 	 
	 	(e)	the
    certificates representing the BriaCell Payment Shares will bear such legends as required by Securities Laws and the policies
    of the Exchange and it is the responsibility of the Sapientia Shareholder to find out what those restrictions are and to comply
    with them before selling the BriaCell Payment Shares; and
	 	 	 
	 	(f)	they
    are knowledgeable of, or has been independently advised as to, the applicable laws of that jurisdiction which apply to the
    sale of the Sapientia Shares and the issuance of the BriaCell Payment Shares and which may impose restrictions on the resale
    of such BriaCell Payment Shares in that jurisdiction and it is the responsibility of the Sapientia Shareholder to find out
    what those resale restrictions are, and to comply with them before selling the BriaCell Payment Shares.

 

ARTICLE
5

REPRESENTATIONS
AND WARRANTIES OF BRIACELL AND THE ACQUIROR

 

BriaCell
and the Acquiror each jointly represent and warrant to Sapientia and the Shareholders as follows:

 

	5.1	Organization
    and Good Standing

 

	 	(a)	BriaCell
    is a corporation duly organized, validly existing and in good standing under the laws of its province of incorporation, and
    has all requisite corporate power and authority to own or hold under lease its properties and assets and to carry on its business
    as now conducted. BriaCell is duly qualified to do business and is in good standing in every jurisdiction in which a failure
    to so qualify could have a material adverse effect upon its properties, assets, financial condition, results of operation
    or business prospects.

 

    	 	 	 

    	 	-11-	 

    

 

	 	(b)	The
    Acquiror is a corporation duly organized, validly existing and in good standing under the laws of its state of incorporation,
    and has all requisite corporate power and authority to own or hold under lease its properties and assets and to carry on its
    business as now conducted. It is the intention of the parties that Sapientia, following the Closing Date, continue to qualify
    for scientific research and development grants in the United States.

 

	5.2	Authorization

 

Each
of BriaCell and the Acquiror have all requisite power and authority to execute and deliver this Agreement and all other agreements
and documents to be executed and delivered by BriaCell and the Acquiror pursuant hereto and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement and all other agreements and documents to be executed and delivered by BriaCell
and the Acquiror pursuant hereto, and the consummation of the transactions contemplated hereby and thereby have been duly authorized
by all necessary action on BriaCell’s and the Acquiror’s part and this Agreement and all other agreements and documents
to be executed and delivered by each of BriaCell and the Acquiror pursuant hereto constitute the valid and binding agreements
of BriaCell and the Acquiror enforceable against each of BriaCell and the Acquiror in accordance with their respective terms (subject,
as to the enforcement of remedies, to general principles of equity and to bankruptcy, insolvency and similar laws affecting creditors’
rights generally). Other than the acceptance of the Exchange, no consent of, or notice to, any federal, state or local authority,
or any other person or entity is required to be obtained or made by BriaCell in connection with the execution, delivery and performance
of this Agreement and the other agreements and documents to be executed, delivered and performed by BriaCell pursuant hereto.

 

	5.3	No
    Violation

 

Neither
the execution and delivery of this Agreement, nor the consummation of the transactions contemplated hereby will constitute a violation
of, or be in conflict with, or result in a cancellation of, or constitute a default under, or create (or cause the acceleration
of the maturity of) any debt, obligation or liability affecting, or result in the creation or imposition of any security interest,
lien, or other encumbrance upon any of the assets owned or used by, or any of the capital stock of, BriaCell or the Acquiror under:

 

	 	(a)	any
    term or provision of the certificate of incorporation or by-laws (or other organic document) of BriaCell or the Acquiror;
	 	 	 
	 	(b)	any
    contract, agreement, indenture, lease or other commitment to which BriaCell or the Acquiror are party or by which or the Acquiror
    are bound;
	 	 	 
	 	(c)	any
    judgment, decree, order, regulation or rule of any court or governmental authority; or
	 	 	 
	 	(d)	any
    statute or law.

 

    	 	 	 

    	 	-12-	 

    

 

	5.4	Reporting
    Issuer Status; Listing

 

BriaCell
is a “reporting issuer” under securities legislation in force in each of the provinces of British Columbia and Alberta
is not in default in any material respect of any requirement under such legislation. The BriaCell Shares are listed for trading
on the Exchange.

 

	5.5	Public
    Record

 

All
information and statements filed by or on behalf of BriaCell with applicable securities regulatory authorities were true, correct
and complete in all material respects and did not contain any misrepresentation as of the date of such information or statements,
and BriaCell has not filed any confidential material change reports still maintained on a confidential basis under applicable
securities Laws.

 

	5.6	Share
    Capital

 

	 	(a)	The
    authorized capital of BriaCell consists of an unlimited number of BriaCell Shares, of which 105,867,560 BriaCell Shares are
    issued and outstanding, all of such BriaCell Shares have been duly authorized and validly issued and are outstanding as fully-paid
    and non-assessable shares. The outstanding options, warrants and other convertible securities or rights capable of becoming
    an equity interest in BriaCell are accurately disclosed in the public record. The BriaCell Payment Shares be issued to the
    Sapientia Shareholders in accordance with the terms hereof shall be fully paid, non-assessable shares in the capital of BriaCell.
	 	 	 
	 	(b)	The
    authorized capital of the Acquiror consists of an unlimited number of common stock of which 10,000 shares are currently issued
    and outstanding, all of such shares of the Acquiror have been duly authorized and validly issued and are outstanding as fully-paid
    and non-assessable shares in the capital of the Acquiror. BriaCell is the sole registered and beneficial holder of all of
    the shares in the capital of the Acquiror.

 

	5.7	No
    Significant Acquisition

 

The
transactions contemplated by this Agreement does not constitute a “Significant Acquisition” (as such term is defined
in National Instrument 51-102 – Continuous Disclosure Obligations) by BriaCell.

 

	5.8	MI
    61-101 Exemptions

 

To
the extent that the transactions contemplated by this Agreement constitute a “related-party transaction” (as such
term is defined in Policy 5.9 of the Corporate Finance Manual and under Multilateral Instrument 61-101 – Protection of
Minority Security Holders in Special Transactions (“MI 61-101”)), one or more exemptions are available
from the minority approval and formal valuation requirements prescribed by MI 61-101.

 

    	 	 	 

    	 	-13-	 

    

 

ARTICLE
6

COVENANTS
OF SAPIENTIA

 

Sapientia
covenants and agrees with BriaCell that from the date hereof until the Closing or other termination of this Agreement, without
the prior written consent of BriaCell:

 

	6.1	Operations

 

Except
as otherwise expressly permitted by the terms hereof or as otherwise agreed to in writing by BriaCell:

 

	 	(a)	Sapientia
    shall operate and conduct its business and operate its assets in the normal course of business and in substantial compliance
    with all applicable laws, rules and regulations;
	 	 	 
	 	(b)	Sapientia
    shall maintain and preserve its rights in the Intellectual Property;
	 	 	 
	 	(c)	Sapientia
    shall not create any liability, debt or obligation other than in furtherance of this transaction;
	 	 	 
	 	(d)	Sapientia
    shall not amend any of its constating documents or by-laws; and
	 	 	 
	 	(e)	Sapientia
    shall not take, agree to take, or knowingly permit to be taken any action or do or knowingly permit to be done anything in
    the conduct of its business, or otherwise, which would be contrary to or in breach of any of the terms or provisions of this
    Agreement, or (except as expressly contemplated by this Agreement) which would cause any of the representations, warranties
    or covenants of Sapientia contained herein to be or become untrue.

 

	6.2	Additional
    Information

 

Sapientia
will make available to BriaCell and its authorized agents and accountants for inspection, at reasonable times and under reasonable
circumstances, assets, business and financial records, management reports, all tax returns and working papers of Sapientia, files
and memoranda of their public accountants and outside legal counsel and relevant materials relating its assets or business for
the purpose of making such accounting review, legal and audit investigation or examination deemed desirable by BriaCell.

 

	6.3	Publicity

 

None
of Sapientia, the Sapientia Shareholders or any employee, agent, attorney, officer or public accountant of any Sapientia Shareholder
or BriaCell shall issue any oral or written publicity regarding this transaction without prior consultation with and approval
of BriaCell.

 

    	 	 	 

    	 	-14-	 

    

 

ARTICLE
7 

CONDITIONS
TO CLOSING

 

	7.1	Mutual
    Conditions

 

The
respective obligations of each party to consummate the transactions contemplated by this Agreement shall be subject to the condition
that no suit, action or other proceeding or investigation shall to the knowledge of any party hereto be threatened or pending
before or by any governmental agency or by any third party questioning the legality of this Agreement or the consummation of the
transactions contemplated hereby in whole or in part.

 

	7.2	Conditions
    to the BriaCell’s and the Acquiror’s Obligations

 

The
obligations of BriaCell and the Acquiror to consummate the transactions contemplated by this Agreement shall be subject to the
fulfilment at or prior to the closing (the “Closing”) of each of the following conditions:

 

	 	(a)	All
    representations and warranties made by Sapientia or the Sapientia Shareholders contained in this Agreement, in the Schedules
    or any other written statement, certificate or other instrument furnished to BriaCell by or on behalf of the Sapientia Shareholders
    and Sapientia pursuant to this Agreement, shall be true and correct on the date hereof and as of the Closing Date as though
    such representations and warranties were made as of the Closing Date, and Sapientia and the Sapientia Shareholders shall have
    duly performed or complied with all of the obligations to be performed or complied with by it or him under the terms of this
    Agreement on or prior to Closing.
	 	 	 
	 	(b)	The
    Sapientia Shareholders and Sapientia shall have complied with and performed all agreements, covenants and conditions in this
    Agreement required to be performed and complied with by them on or before the Closing Date, and that all requisite action
    (corporate and other) in order to consummate this Agreement shall have been properly taken by the Sapientia Shareholders and
    Sapientia.
	 	 	 
	 	(c)	No
    material adverse change shall have occurred in the condition (financial or otherwise) of Sapientia, its assets or its business
    considered as a whole.
	 	 	 
	 	(d)	All
    material authorizations, consents, waivers, Approvals or other action required in connection with the execution, delivery
    and performance of this Agreement by the Sapientia Shareholders and the consummation by the Sapientia Shareholders of the
    transactions contemplated hereby shall have been obtained, and Sapientia or the Sapientia Shareholders shall have obtained
    any authorizations, consents, waivers, approvals or other action required in connection with the execution, delivery and performance
    of this Agreement to prevent a material breach or default by Sapientia or the Sapientia Shareholders under any contract to
    which Sapientia or the Sapientia Shareholders is or are a party or for the continuation of any agreement to which Sapientia
    is a party and which relates and is material to the business of  Sapientia.
	 	 	 
	 	(e)	The
    Sapientia Shareholders shall have delivered to BriaCell all instruments of assignment, transfer and conveyance of the Sapientia
    Shares, including, without limitation, properly executed stock powers (assignments separate from certificate) and such other
    closing documents as shall have been reasonably requested by BriaCell, all in form and substance reasonably acceptable to
    Sapientia’s counsel.

 

    	 	 	 

    	 	-15-	 

    

 

	 	(f)	On
    the Closing, provided such persons meet all necessary legal and regulatory requirements and are willing and able to act in
    the positions shown below, the directors and officers of Sapientia shall consist of the following persons:

 

	 	(i)	Dr.
    William Williams (Chief Executive Officer and director);
	 	 	 
	 	(ii)	Martin
    Schmieg (Chief Financial Officer and director); and
	 	 	 
	 	(iii)	James
    Hoffman (Chief Operating Officer).

 

	 	 	Sapientia
    shall take all necessary steps to obtain resignations of existing directors and officers in order for these appointments to
    be effective on Closing.
	 	 	 
	 	(g)	At
    the Closing, Sapientia shall deliver resignations of those directors and officers of Sapientia who are either not continuing
    with Sapientia or are continuing in a different capacity or role, such resignations to include waivers in respect of any liabilities
    of Sapientia to them in a form acceptable to BriaCell, acting reasonably.
	 	 	 
	 	(h)	BriaCell
    shall have received evidence, satisfactory to BriaCell and its counsel, that any unanimous shareholders agreement (if any
    exist) or similar agreement has been terminated on or prior to Closing or, in the alternative, that no unanimous shareholders
    agreement exists.
	 	 	 
	 	(i)	BriaCell
    shall have satisfactorily completed its due diligence review and audit of Sapientia’s books and records and operations.
	 	 	 
	 	(j)	Subject
    to the terms and conditions set forth herein, the parties hereto acknowledge and agree that Sapientia shall be required: (i)
    to deliver the Financial Statements to BriaCell as promptly as reasonably practicable, but in any event no later than 15 days
    after the Closing Date; (ii) notify Faller & Williams Technology LLC of the Closing Date as soon as practicable following
    the date thereof and in any event within 30 days after the Closing Date (collectively, the “Post-Closing Obligations”).
    The Post- Closing Obligations shall be deemed incorporated by reference herein as fully as if set forth herein in their entirely.
    All conditions precedent, representations and covenants contained in this Agreement shall be deemed modified to the extent
    necessary to effect the foregoing.

 

	7.3	Conditions
    to the Sapientia and Sapientia Shareholders’ Obligations

 

The
obligations of the Sapientia Shareholders and Sapientia to consummate the transactions contemplated by this Agreement shall be
subject to the fulfilment at or prior to the Closing of each of the following conditions:

 

	 	(a)	The
    representations and warranties of BriaCell and the Acquiror contained in this Agreement shall be true and correct on the date
    hereof and as of the Closing Date as though such representations and warranties were made as of the Closing Date, and each
    of BriaCell and the Acquiror shall have duly performed or complied with all of the obligations to be performed or complied
    with by it under the terms of this Agreement on or prior to Closing.

 

    	 	 	 

    	 	-16-	 

    

 

	 	(b)	All
    material authorizations, consents, waivers, approvals or other action required in connection with the execution, delivery
    and performance of this Agreement by each of BriaCell and the Acquiror, and the consummation by BriaCell of the transactions
    contemplated hereby, shall have been obtained including the approval of the Exchange.
	 	 	 
	 	(c)	BriaCell
    shall have complied with and performed all agreements, covenants and conditions in this Agreement required to be performed
    and complied with by it on or before the Closing Date, and that all requisite action (corporate and other) in order to consummate
    this Agreement shall have been properly taken by BriaCell.
	 	 	 
	 	(d)	No
    material adverse change shall have occurred in the condition (financial or otherwise) of BriaCell, its assets or its business.

 

ARTICLE
8

TERMINATION

 

	8.1	Termination
    of Agreement

 

This
Agreement and the transactions contemplated hereby may be terminated at any time prior to Closing, as follows:

 

	 	(a)	By
    mutual consent of the parties hereto.
	 	 	 
	 	(b)	By
    BriaCell on the one hand or by Sapientia on the other hand by reason of the breach by the other in any material respect of
    any of its or their representations, warranties, covenants or agreements contained in this Agreement which is not cured within
    five days from the date of written notice of such breach.
	 	 	 
	 	(c)	By
    BriaCell on the one hand or by the Sapientia Shareholders on the other hand if the conditions precedent to their respective
    obligations contained in Sections 7.2 or 7.3 hereof have not been met in all material respects by April 30, 2017 or such later
    date as may be agreed in writing by BriaCell and Sapientia (on its own behalf and on behalf of the Sapientia Shareholders).
	 	 	 
	 	(d)	By
    BriaCell on the one hand or by the Sapientia Shareholders on the other hand if any of the conditions described in Section
    7.1 shall not have been fulfilled by April 30, 2017 or such later date as may be agreed in writing by BriaCell and Sapientia
    (on its own behalf and on behalf of the Sapientia Shareholders).
	 	 	 
	 	(e)	In
    the event of termination of this Agreement by reason of the breach by any party, then the non-offending party shall have full
    recourse for any and all loss, costs, damages or liability suffered or incurred by them as a result of the breach by April
    30, 2017 or such later date as may be agreed in writing by BriaCell and Sapientia (on its own behalf and on behalf of the
    Sapientia Shareholders).

 

    	 	 	 

    	 	-17-	 

    

 

ARTICLE
9

SURVIVAL
OF REPRESENTATIONS AND WARRANTIES

 

The
representations and warranties contained in Article 4 and Article 5 shall survive the Closing Date for a period of 24 months.

 

ARTICLE
10

GENERAL
PROVISIONS

 

	10.1	Waiver
    of Terms

 

Except
as otherwise permitted or required hereunder, any of the terms or conditions of this Agreement may be waived at any time by the
party or parties entitled to the benefit thereof only by a written notice signed by the party or parties waiving such terms or
conditions.

 

	10.2	Amendment
    of Agreement

 

Except
as otherwise permitted or required hereunder, this Agreement may be amended, supplemented or interpreted at any time only by written
instrument duly executed by each of the Sapientia Shareholders, Sapientia and BriaCell.

 

	10.3	Payment
    of Expenses

 

The
Sapientia Shareholders and BriaCell shall each pay their or its own expenses, including, without limitation, the expenses of their
or its own counsel, investment bankers and accountants, incurred in connection with the preparation, execution and delivery of
this Agreement and the other agreements and documents referred to herein and the consummation of the transactions contemplated
hereby and thereby.

 

	10.4	Contents
    of Agreement, Parties in Interest, Assignment

 

This
Agreement and the other agreements and documents referred to herein set forth the entire understanding of the parties with respect
to the subject matter hereof. Any previous agreements or understandings between the parties regarding the subject matter hereof
are superseded by this Agreement. All representations, warranties, covenants, terms and conditions of this Agreement shall be
binding upon and inure to the benefit of and be enforceable by the respective heirs, legal representatives, successors and permitted
assigns of the parties hereto.

 

	10.5	Independent
    Legal Advice

 

EACH
OF THE PARTIES TO THIS AGREEMENT ACKNOWLEDGES AND AGREES THAT BENNETT JONES LLP HAS ACTED AS COUNSEL ONLY TO BRIACELL AND THAT
BENNETT JONES LLP IS NOT PROTECTING THE RIGHTS AND INTERESTS OF SAPIENTIA OR THE SAPIENTIA SHAREHOLDERS. SAPIENTIA AND THE SAPIENTIA
SHAREHOLDERS ACKNOWLEDGE AND AGREE THAT BRIACELL AND BENNETT JONES LLP HAVE GIVEN THEM THE OPPORTUNITY TO SEEK INDEPENDENT LEGAL
ADVICE WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT AND, FURTHER, THE SAPIENTIA SHAREHOLDERS HEREBY REPRESENT AND WARRANT
TO THE ACQUIROR, BRIACELL, SAPIENTIA, AND BENNETT JONES LLP THAT THEY HAVE SOUGHT INDEPENDENT LEGAL ADVICE OR WAIVE SUCH ADVICE.

 

    	 	 	 

    	 	-18-	 

    

 

	10.6	Notices

 

All
notices, requests, demands and other communications required or permitted to be given hereunder shall be by hand-delivery, e-mail,
certified or registered mail, return receipt requested; telex, telecopier, or next day air courier to the parties set forth below.
Such notices shall be deemed given: at the time personally delivered, if delivered by hand; three days after deposit in the Canadian
mail, if sent by registered mail; upon delivery, with receipt acknowledged, if telecopied; and the next business day after timely
delivery to the courier, if sent by courier.

 

If
to BriaCell or the Acquiror:

 

Suite
300 – 235 15th Street

West
Vancouver, British Columbia V7T 2X1

 

	 	Attention:	Dr.
    Saied Babaei, Chairman
	 	 	 
	 	E-mail:	sbabaei@briacell.com

 

With
a copy to:

 

Bennett
Jones LLP

100
King Street West

One
First Canadian Place, Suite 3400

Toronto,
Ontario M4X 1A4

 

	 	Attention:	Aaron
    Sonshine, Partner
	 	 	 
	 	E-mail:	sonshinea@bennettjones.com

 

If
to Sapientia and the Sapientia Shareholders:

 

Suite
303 - 2015 N. Federal Hwy

Delray
Beach, Florida 33483

 

	 	Attention:	Dr.
    William Williams 
	 	 	 
	 	E-mail:	wiliams@briacell.com

 

Any
party hereto may change its notice address by proper notice to the other parties.

 

	10.7	Severability

 

In
the event that any one or more of the provisions contained in this Agreement shall be invalid, illegal or unenforceable in any
respect for any reason, the validity, legality and enforceability of any such provision in every other respect and of the remaining
provisions of this Agreement shall not be in any way impaired.

 

    	 	 	 

    	 	-19-	 

    

 

	10.8	Counterparts

 

This
Agreement may be executed (by original, fax or other electronic transmission) in two or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument.

 

	10.9	Headings

 

The
headings of the Sections and the subsections of this Agreement are inserted for convenience of reference only and shall not constitute
a part hereof.

 

	10.10	Governing
    Law; Jurisdiction

 

This
Agreement shall, in all respects, be subject to, interpreted, construed and enforced in accordance with and under the laws of
the Province of British Columbia and applicable laws of Canada.

 

	10.11	Attornment

 

The
parties each attorn to the non-exclusive jurisdiction of the courts of the Province of British Columbia.

 

	10.12	Instruments
    of Further Assurance

 

Each
of the parties hereto agrees, upon the request of any of the other parties hereto, from time to time to execute and deliver to
such other party or parties all such instruments and documents of further assurance or otherwise as shall be reasonable under
the circumstances, and to do any and all such acts and things as may reasonably be required to carry out the obligations of such
requested party hereunder.

 

	10.13	Currency

 

All
monetary amounts expressed in this Agreement and all payments required by this Agreement are and shall be in Canadian dollars.

 

[Remainder
of page intentionally left blank]

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

		 	
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

		 	
	Witness	 	Dr.
    William Williams
	 	 	 
		 	
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

	 	 	 
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
		 	
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

	 	 	 
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
		 	
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

	 	 	 
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
		 	
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

	 	 	 
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
		 	
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

	 	 	 
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
		 	
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
	 	 	 
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto on the day and year first above written.

 

SIGNED,
SEALED & DELIVERED

in
the presence

 

	 	 	 
	Witness	 	Dr.
    William Williams
	 	 	 
	 	 	 
	Witness	 	James
    Hoffman
	 	 	 
	 	 	 
	Witness	 	Martin
    Schmieg
	 	 	 
	 	 	 
	Witness	 	Douglas
    Faller
	 	 	 
	 	 	 
	Witness	 	Robert
    Williams
	 	 	 
	 	 	 
	Witness	 	Edward
    McKeever
	 	 	 
	 	 	 
	Witness	 	Susan
    Erickson Viitanen
	 	 	 
		 	
	Witness	 	Shui
    He

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

		 	
	Witness	 	Kevin
    Hou
	 	 	 
	 	 	 
	Witness	 	John
    Hand
	 	 	 
	 	 	 
	Witness	 	Mike
    Tomas
	 	 	 
	 	 	 
	Witness	 	James
    Seibold
	 	 	 
	 	 	 
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	 
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

	 	 	 
	Witness	 	Kevin
    Hou
	 	 	 
		 	
	Witness	 	John
    Hand
	 	 	 
	 	 	 
	Witness	 	Mike
    Tomas
	 	 	 
	 	 	 
	Witness	 	James
    Seibold
	 	 	 
	 	 	 
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	 
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

	 	 	 
	Witness	 	Kevin
    Hou
	 	 	 
	 	 	 
	Witness	 	John
    Hand
	 	 	 
		 	
	Witness	 	Mike
    Tomas
	 	 	 
	 	 	 
	Witness	 	James
    Seibold
	 	 	 
	 	 	 
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	 
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

	 	 	 
	Witness	 	Kevin
    Hou
	 	 	 
	 	 	 
	Witness	 	John
    Hand
	 	 	 
	 	 	 
	Witness	 	Mike
    Tomas
	 	 	 
		 	
	Witness	 	James
    Seibold
	 	 	 
	 	 	 
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	 
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

	 	 	 
	Witness	 	Kevin
    Hou
	 	 	 
	 	 	 
	Witness	 	John
    Hand
	 	 	 
	 	 	 
	Witness	 	Mike
    Tomas
	 	 	 
	 	 	 
	Witness	 	James
    Seibold
	 	 	 
		 	
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	 
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

	 	 	 
	Witness	 	Kevin
    Hou
	 	 	 
	 	 	 
	Witness	 	John
    Hand
	 	 	 
	 	 	 
	Witness	 	Mike
    Tomas
	 	 	 
	 	 	 
	Witness	 	James
    Seibold
	 	 	 
	 	 	 
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

	 	 	 
	Witness	 	Kevin
    Hou
	 	 	 
	 	 	 
	Witness	 	John
    Hand
	 	 	 
	 	 	 
	Witness	 	Mike
    Tomas
	 	 	 
	 	 	 
	Witness	 	James
    Seibold
	 	 	 
	 	 	 
	Witness	 	Maria
    Trojanowska
	 	 	 
	 	 	 
	Witness	 	Steven
    Krivicich

 

	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:		 
	 	Authorized
    Signing Officer	 
	 	 	 
	BRIACELL
    THERAPEUTICS CORP.	 
	 	 	 
	Per:	 	 
	 	Authorized
    Signing Officer	 
	 	 	 
	SAPIENTIA
    PHARMACEUTICALS, INC.	 
	 	 
	Per:		 
	 	Authorized
    Signing Officer	 

 

Signature
Page to Share Exchange Agreement

 

    	 	 	 

     

    

 

EXHIBIT
“A”

 

	1.	Dr.
    William Williams
	 	 
	2.	James
    Hoffman
	 	 
	3.	Martin
    Schmieg
	 	 
	4.	Douglas
    Faller
	 	 
	5.	Robert
    Williams
	 	 
	6.	Edward
    McKeever
	 	 
	7.	Susan
    Erickson Viitanen
	 	 
	8.	Shui
    He
	 	 
	9.	Kevin
    Hou
	 	 
	10.	John
    Hand
	 	 
	11.	Mike
    Tomas
	 	 
	12.	James
    Seibold
	 	 
	13.	Maria
    Trojanowska
	 	 
	14.	Steven
    Krivicich

 

    	 	 	 

     

    

 

SCHEDULE
2.1(A)

 

SAPIENTIA
SHARES

 

	Name
                                         of Sapientia

        Shareholder
	 	Sapientia
                                         Shares

                                                                                Owned
	 	Percentage
                                         of Total Sapientia

        Shares
        Owned

	 	 	 	 	 
	Dr.
    William Williams	 	2,052,653	 	49.5%
	 	 	 	 	 
	James
    Hoffman	 	1,051,000	 	25.4%
	 	 	 	 	 
	Martin
    Schmieg	 	120,000	 	2.9%
	 	 	 	 	 
	Douglas
    Faller	 	406,750	 	9.8%
	 	 	 	 	 
	Robert
    Williams	 	406,750	 	9.8%
	 	 	 	 	 
	Edward
    McKeever	 	5,000	 	0.1%
	 	 	 	 	 
	Susan
    Erickson Viitanen	 	5,000	 	0.1%
	 	 	 	 	 
	Shui
    He	 	10,000	 	0.2%
	 	 	 	 	 
	Kevin
    Hou	 	10,000	 	0.2%
	 	 	 	 	 
	John
    Hand	 	10,000	 	0.2%
	 	 	 	 	 
	Mike
    Tomas	 	10,000	 	0.2%
	 	 	 	 	 
	James
    Seibold	 	6,000	 	0.1%
	 	 	 	 	 
	Maria
    Trojanowska	 	50,000	 	1.2%
	 	 	 	 	 
	Steven
    Krivicich	 	1,000	 	0.0%
	 	 	 	 	 
	TOTAL:	 	4,144,153	 	100%

 

    	 	 	 

     

    

 

SCHEDULE
3.9 

 

CONTRACTS

 

	1.	License
    Agreement dated March 16, 2017 by and between Sapientia Pharmaceuticals, Inc. and Faller & Williams Technology LLC.

 

    	 	 	 

     

    

 

SCHEDULE
3.13 

 

PATENTS,
ETC.

 

	1.	U.S.
    Provisional Application No. 61/703,081 entitle “PKC Delta Inhibitors for use as Therapeutics” filed 19 September
    2012 .
	 	 
	2.	International
    Application No. PCT/US2013/60638 entitled “PKC Delta Inhibitors for use as Therapeutics” filed 19 September 2013.
	 	 
	3.	U.S.
    Patent No. 9,364,460 entitled “PKC Delta Inhibitors for use as Therapeutics” issued 14 June 2016.
	 	 
	4.	U.S.
    Patent Application No. 15/148,420 entitled “PKC Delta Inhibitors for use as Therapeutics” filed 06 May 2016.
	 	 
	5.	U.S.
    Patent Application No. 15/425,381 entitled “PKC Delta Inhibitors for use as Therapeutics” filed 06 February 2017.
	 	 
	6.	EP
    Patent Application No. 13839158.6 “PKC Delta Inhibitors for use as Therapeutics” filed 25 March 2015.Clinical
Trial Agreement

 

This
Clinical Trial Agreement (“Agreement”) is made on 1/26/2018 (the “Effective Date”) by and between
St. Joseph Heritage Healthcare (“Institution”), a California nonprofit public benefit corporation with an address
at 200 W. Center Street Promenade, Suite 800, Anaheim, California 92805; Jarrod Holmes, M.D. (“Principal Investigator”),
a contractor of Institution with an office located at 3555 Round Barn Circle, Santa Rosa, CA 95403, and Cancer Insight, LLC (“CRO”),
a limited liability company having its principal place of business at 110 E. Houston Street, San Antonio, TX 78205. CRO, Institution
and Principal Investigator are herein referred to collectively as “Parties.” Individually, each of CRO and Institution
is a “Party.”

 

WHEREAS,
CRO has been engaged by BriaCell Therapeutics (the “Sponsor”) to arrange and administer a multi-center clinical trial
funded by Sponsor to determine the safety and efficacy of Sponsor’s product;

 

WHEREAS,
Sponsor is a for-profit organization that intends to conduct a sponsored multi-center clinical trial, described in 1.1 below,
involving the use of certain diagnostic(s), drug(s), devices(s), or biologic(s) provided by Sponsor and desires that
Institution participate in such clinical trial;

 

WHEREAS,
Institution, Principal Investigator, Sponsor and CRO have agreed to use this Clinical Trial Agreement, to facilitate the process
of translating laboratory discoveries into treatments for patients, to engage communities in clinical research efforts, and to
train a new generation of clinical and translational researchers;

 

WHEREAS,
the Institution has appropriate facilities and personnel with the qualification, training, knowledge, and experience necessary
to conduct such a clinical trial; and

 

WHEREAS,
the Study contemplated by this Agreement is of interest and benefit to Institution, Principal Investigator, Sponsor and CRO, and
will further the instructional and research objectives of Institution in a manner consistent with its status as a nonprofit educational,
research and health care institution;

 

NOW,
THEREFORE, in consideration for the mutual promises made in this Agreement and for valid consideration, the Parties agree
as follows:

 

1.
Scope of Agreement

 

1.1.
Institution and Principal Investigator will undertake a sponsored multi-center clinical trial (“Study”)
described in the protocol as “A Phase I/IIa Rollover Study of the Whole-Cell Vaccine BriaVaxTM in Metastatic or
Locally Recurrent Breast Cancer Patients in Combination with Ipilimumab or Pembrolizumab,” which is incorporated
herein as Exhibit A (“Protocol”). Institution and Principal Investigator will use its reasonable efforts
to only recruit subjects in accordance with the Protocol. The Study will be conducted by the Institution under the direction
of Principal Investigator.

 

1.2.
In the event of any conflict between the terms and conditions of this Agreement and the Protocol or between this Agreement and
any of its Exhibits, the terms and conditions of the Protocol shall control with respect to matters of the clinical conduct of
the Study, and the terms of this Agreement shall control with respect to all other matters.

 

    	 	 	 

    	 

    

 

1.3.
Unless otherwise agreed to by the Parties, Sponsor and/or CRO will provide to Institution and Principal Investigator on a timely
basis, without charge, the required quantities of properly-labeled Sponsor drug(s) or biologics(s) (“Study Drug”)
and/or device(s) (“Study Device”) and other materials (e.g., Investigator’s Brochure, handling and storage instructions,
and, if applicable, placebo) necessary for Institution and Principal Investigator to conduct the Study in accordance with the
Protocol. Unless stated otherwise in writing by Sponsor, all such items are and will remain the sole property of Sponsor until
administered or dispensed to Study subjects during the course of the Study. Receipt, storage, and handling of Study Drug or Study
Device will be in compliance with all applicable laws and regulations, the Protocol, and CRO’s or Sponsor’s instructions.

 

1.4.
CRO, Institution, and Principal Investigator shall comply with and conduct all aspects of the Study in compliance with all
applicable federal, state, and local laws and regulations, including generally accepted standards of good clinical practice
as adopted by current FDA regulations and statutes and regulations of the U.S. Government relating to exportation of
technical data, computer software, laboratory prototypes, and other commodities as applicable to academic institutions.
Institution and Principal Investigator will only allow individuals who are appropriately trained and qualified to assist in
the conduct of the Study.

 

1.5.
Principal Investigator shall obtain IRB approval for this Study and proof thereof shall be provided to CRO. Initiation of
the Protocol and Institution’s and Principal Investigator’s obligation to conduct the Study shall not begin until
IRB approval is obtained. Principal Investigator shall obtain from each subject, prior to the subject’s participation
in the Study, a signed informed consent and necessary authorization to disclose health information to CRO and/or Sponsor in a
form approved in writing by the IRB or a waiver of consent as directed by the IRB and further provided that the informed
consent is consistent with Institution’s policies.

 

1.6.
Institution or Principal Investigator shall promptly inform Sponsor of any urgent safety measures as instructed in the Protocol
or breaches of the Protocol of which Institution or Principal Investigator becomes aware.

 

1.7.
Institution and Principal Investigator acknowledge CRO’s right to assign or transfer, in whole or in part, with notice to
Institution and Principal Investigator, any of its rights or obligations under this Agreement to the Sponsor or Sponsor’s
designate. Notwithstanding the foregoing, no Party may transfer, assign or otherwise convey its rights or obligations under this
Agreement without the written consent of the other Parties, and any attempt to transfer, assign or otherwise convey any rights
or obligations in violation of this Section 1.7 shall be void.

 

2.
Payments

 

Sponsor
will provide financial support for the Study and will provide such funds to CRO who will pay Institution in accordance with
the budget attached as Exhibit B (“Budget”) on a prorated basis, according to the actual work completed
and any non-cancelable obligated expenses, for subjects who are enrolled into the Study. The Parties acknowledge that the
Budget amounts represent an equitable exchange for the conduct of the Study in light of the professional time and expenses
required for the performance of the Study. Institution has no obligation to order, purchase, or recommend the ordering or
purchasing of any item or service manufactured or distributed by Sponsor.

 

In
addition to other necessary routing information detailed in Exhibit B, each payment shall clearly reference the: Study Protocol
Number and PI name.

 

    	 	 	 

    	 

    

 

For
administrative convenience, various Study contact information may be attached hereto and incorporated by reference as Exhibit
C, entitled, “Administrative & Study Points of Contact.”

 

The
Institution’s tax identification number is: 33-0185031.

 

3.
Confidentiality

 

3.1.
It is anticipated that in the performance of this Agreement, Sponsor and/or CRO on behalf of Sponsor may need to disclose to Institution
and Principal Investigator information which is considered confidential. The rights and obligations of the Parties with respect
to such information are as follows:

 

“Confidential
Information” refers to information of any kind which is disclosed to the Institution or Principal Investigator by
Sponsor and/or CRO on behalf of Sponsor for purposes of conducting the Study or Data (as defined below in Section 4)
which:

 

	 	a)	by appropriate
    marking, is identified as confidential and proprietary at the time of disclosure;
	 	 	 
	 	b)	if disclosed orally,
    is identified in a marked writing within thirty (30) days as being confidential; or
	 	 	 
	 	c)	is of such a nature
    that a reasonable person familiar with the Study would consider it to be confidential or proprietary from the context or circumstances
    of disclosure. Notwithstanding the foregoing, Data and results generated in the course of conducting the Study are not Confidential
    Information for publishing purposes in accordance with Section 9 of this Agreement.

 

Institution
and Principal Investigator each agrees, for a period of five (5) years following the termination or expiration of this Agreement,
to use reasonable efforts, no less than the protection given their own confidential information, to use Confidential Information
received from Sponsor and/or CRO on behalf of Sponsor in accordance with this Section.

 

Institution
and Principal Investigator each agrees to use Sponsor’s Confidential Information solely as allowed by this Agreement,
and for the purposes of conducting the Study. Institution and Principal Investigator each agrees to make Sponsor’s
Confidential Information available only to those of its, or its affiliates’ employees, IRB members, personnel, agents,
consultants, and vendors, and approved subcontractors, as applicable, who require access to it in the performance of this
Study, and are subject to similar terms of confidentiality.

 

3.2.
The obligation of nondisclosure does not apply with respect to any of the Confidential Information that:

 

	 	a)	is or
    becomes public knowledge through no breach of this Agreement by Institution or Principal Investigator;
	 	 	 
	 	b)	is disclosed to
    Institution or Principal Investigator by a third party entitled to disclose such information without known obligation of confidentiality;
	 	 	 
	 	c)	is already known
    or is independently developed by Institution or Principal Investigator without use of Sponsor’s Confidential Information
    as shown by Institution’s or Principal Investigator’s contemporaneous written records;

 

    	 	 	 

    	 

    

 

	 	d)	is necessary
    to obtain IRB approval of Study or required to be included in the written information summary provided to Study subject(s)
    and/or informed consent form;
	 	 	 
	 	e)	is released with
    the prior written consent of the Sponsor; or
	 	 	 
	 	f)	is required to support
    the medical care of a Study Subject.

 

3.3.
Institution and Principal Investigator may disclose Confidential Information to the extent that it is required to be
produced pursuant to a requirement of applicable law, government agency, an order of a court of competent jurisdiction, or a
facially valid administrative, Congressional, or other subpoena, provided that Institution or Principal Investigator, subject
to the requirement, order, or subpoena, promptly notifies Sponsor. Sponsor may seek to limit the scope of such disclosure
and/or seek to obtain a protective order. Institution and Principal Investigator will disclose only the minimum amount of
Confidential Information necessary to comply with law or court order as advised by Institution’s or Principal
Investigator’s legal counsel.

 

3.4.
No license or other right is created or granted hereby, except the specific right to conduct the Study as set forth by Protocol
and under terms of this Agreement, nor shall any license or other right with respect to the subject matter hereof be created or
granted except by the prior written agreement of the Parties duly signed by their authorized representatives.

 

3.5.
Upon Sponsor’s and/or CRO’s written request, Institution and Principal Investigator each agrees to return all Confidential
Information supplied to it/him/her by Sponsor and/or CRO on behalf of Sponsor at Sponsor’s expense pursuant to this Agreement
except that Institution and Principal Investigator may each retain one (1) copy of any such Confidential Information in a secure
location for purposes of identifying and satisfying its/his/her obligations and exercising its/his/her rights under this Agreement.

 

3.6
Institution and Principal Investigator may disclose the existence of this Agreement and any additional information necessary to
ensure compliance with applicable Federal, State and Institutional policies, regulations, and laws.

 

4.
Data Use/Ownership

 

“Data”
shall mean all data and information generated by Institution and Principal Investigator as a result of conducting the Study in
accordance with the IRB approved Protocol. Data does not include original Study subject or patient medical records, research notebooks,
source documents, or other routine internal documents kept in the Institution’s or Principal Investigator’s ordinary
course of business operations, which shall remain the sole and exclusive property of the Institution or Principal Investigator.
Sponsor owns and has the right to use the Data in accordance with the signed informed consent and authorization form, applicable
laws, and the terms of this Agreement. Notwithstanding any licenses or other rights granted to Sponsor herein, but in accordance
with the confidentiality and publication sections herein, Institution and Principal Investigator shall retain the right to use
the Data and results for its/his/her publication, IRB, regulatory, legal, clinical, educational, and internal research purposes.

 

    	 	 	 

    	 

    

 

5.
HIPAA/HIPAA Privacy

 

5.1.
Institution and Principal Investigator shall comply with applicable laws and regulations, as amended from time to time, including
without limitation, the Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (HIPAA) with
respect to the collection, use, storage, and disclosure of Protected Health Information (PHI) as defined in HIPAA. CRO and Sponsor
through its agreement with CRO, shall collect, use, store, access, and disclose PHI collected from Study subjects only as permitted
by the IRB approved informed consent form or HIPAA authorization form obtained from a Study subject. Sponsor will collect, use,
store, and disclose any Subject Material, defined in Section 15, it receives only in accordance with the informed consent form
and, in any event, will not collect, use, store, or disclose any PHI attached to or contained within the Subject Material in any
manner that would violate this Section of the Agreement. If Sponsor or CRO contracts with any agents to whom it provides a Study
subject’s PHI, it will include provisions in those agreements through which its agents agree to similar restrictions and
conditions that apply to Sponsor and CRO regarding Study subjects’ PHI.

 

Institution
and Principal Investigator each acknowledges that, pursuant to Section 111 of the Medicare, Medicaid, and SCHIP Extension Act
of 2007 (“MMSEA”), Sponsor has an obligation to submit certain reports to the Centers for Medicare & Medicaid
Services with respect to Medicare beneficiaries who participate in the Study and experience a research injury for which diagnosis
or treatment costs are incurred. Sponsor and CRO recognize that each party is subject to laws and regulations protecting the confidentiality
of research subject information. Accordingly: (1) Institution agrees upon prior written request to provide to Sponsor, or CRO
as designated by Sponsor, certain identifiable patient information required by MMSEA for Study subjects who are Medicare beneficiaries
and incur medical costs in association with a research injury and whose costs are reimbursed by Sponsor pursuant to this Agreement;
and (2) Institution further agrees to otherwise cooperate with Sponsor (and CRO as designated by Sponsor) to the extent necessary
for Sponsor to meet its MMSEA reporting obligations.

 

5.2.
CRO’s ability to review the Study subjects’ Study-related information contained in the Study subject’s medical
record shall be subject to reasonable safeguards for the protection of Study subject confidentiality and the Study subjects’
informed consent form or HIPAA authorization form.

 

5.3.
Neither CRO, nor Sponsor through its agreement with CRO, shall attempt to identify, or contact, any Study subject unless permitted
by the informed consent form.

 

6.
Record Retention

 

As
applicable by law, Institution shall retain and preserve a copy of the Study records for the longer of:

 

	 	a)	two
    (2) years after a marketing authorization for Study Drug, or Study Device has been approved for the indication for which it
    was investigated or Sponsor has discontinued research on the Study Drug or Study Device;
	 	 	 
	 	b)	such longer period
    as required by federal regulatory requirements; or
	 	 	 
	 	c)	as requested by
    Sponsor at Sponsor’s reasonable storage expense.

 

At
the end of such period, the Institution shall notify Sponsor of its intent to destroy any such records. Sponsor shall have thirty
(30) days to respond to the Institution’s notice, and Sponsor shall have the opportunity to preserve such records at Sponsor’s
expense.

 

    	 	 	 

    	 

    

 

7.
Monitoring and Auditing

 

7.1.
Site visits by Sponsor, CRO and/or another authorized designee (e.g., Study monitor) will be scheduled in advance for times mutually
acceptable to the Parties during normal business hours. Sponsor’s, CRO’s and/or authorized designee’s access
is subject to reasonable safeguards to ensure confidentiality of medical records and systems.

 

7.2.
Upon becoming aware of an audit or investigation by a regulatory agency with jurisdiction over the Study, Institution and Principal
Investigator agree to provide Sponsor with prompt notice of the auditor investigation. If legally permissible or allowable by
the regulatory agency and permissible in accordance with the Institution’s policy, Sponsor may be available or request to
be present with approval from auditor during such audit, but Sponsor will not alter or interfere with any documentation or practice
of Institution or Principal Investigator. Institution and Principal Investigator shall be free to respond to any regulatory agency
inquiries and will provide Sponsor with a copy of any formal response or documentation to the regulatory agency regarding the
Study.

 

8.
Inventions, Discoveries and Patents

 

8.1.
It is recognized and understood that certain existing inventions and technologies, and those arising outside of the research conducted
under this Agreement, are the separate property of Sponsor, Institution or Principal Investigator and are not affected by this
Agreement, and neither Sponsor nor Institution nor Principal Investigator shall have any claims to or rights in such separate
inventions and technologies.

 

8.2.
Any new patentable inventions, developments, or discoveries made during and in the performance of the Study (“Inventions”)
shall be promptly disclosed to Sponsor. Title to Inventions that necessarily use or necessarily incorporate Sponsor’s Study
Drug and/or Study Device shall reside with Sponsor (“Sponsor Inventions”). Institution and Principal Investigator
shall assign all Sponsor Inventions to Sponsor in writing. Title to Inventions other than Sponsor Inventions (“Other Inventions”)
shall reside with Sponsor if Sponsor personnel are the sole inventors, with Institution if Institution personnel are the sole
inventors, with Principal Investigator if Principal Investigator is the sole inventor, and shall be held jointly if Institution
and/or Principal Investigator and Sponsor personnel are inventors.

 

8.3.
To the extent that Institution or Principal Investigator owns sole or joint title in any such Other Inventions, Sponsor is
hereby granted, without option fee other than consideration of the Study sponsored herein and the reimbursement to
Institution or Principal Investigator for patent expenses incurred prior to or during the option period, an option to acquire
an exclusive, worldwide, royalty-bearing license to Institution’s or Principal Investigator’s rights to any Other
Invention, which option shall extend for no more than ninety (90) days after Sponsor’s receipt of an Invention
disclosure from Institution or Principal Investigator (“Option Period”). Sponsor and Institution and/or Principal
Investigator shall use their reasonable efforts to negotiate, for a period not to exceed ninety (90) days after
Sponsor’s exercise of such option, a license agreement satisfactory to all parties (“Negotiation Period”).
In the event Sponsor fails to exercise its option within the Option Period, or Sponsor and Institution and/or Principal
Investigator fail to reach agreement on the terms of such license within the Negotiation Period, Institution and Principal
Investigator shall have no further obligation to Sponsor under this Agreement with regard to the specific Other
Invention.

 

8.4.
Institution and Principal Investigator shall retain a royalty-free, irrevocable license to use for its/his/her own internal noncommercial
research, educational and patient care purposes, all Sponsor Inventions or Other Inventions licensed or assigned to Sponsor hereunder.

 

    	 	 	 

    	 

    

 

8.5.
Nothing contained in this Agreement shall be deemed to grant either directly by implication, estoppel, or otherwise any license
under any patents, patent applications, or other proprietary interest to any other inventions, discovery or improvement of either
Sponsor, Institution or Principal Investigator.

 

8.6.
CRO, Institution and Principal Investigator agree that the provisions of this Agreement are intended to be interpreted and
implemented so as to comply with all applicable federal laws, rules, and regulations, including without limitation the
requirements of Rev. Proc. 2007-47; provided, however, if it is determined by the Internal Revenue Service or any other
federal agency or instrumentality (the “Government”) that the provisions of this Agreement are not in such
compliance, then those parties agree to modify the provisions and the implementation of this Agreement so as to be in
compliance with all applicable federal laws, rules, and regulations as determined by the Government.

 

9.
Publication

 

9.1.
Institution and Principal Investigator shall be free to publish, present, or use any Data and results arising out of its performance
of the Protocol (individually, a “Publication”). At least thirty (30) days prior to submission for Publication, Institution
or Principal Investigator shall submit to Sponsor for review and comment any proposed oral or written Publication (“Review
Period”). Institution and Principal Investigator will consider any such comments in good faith but is under no obligation
to incorporate Sponsor’s suggestions. The Review Period for abstracts or poster presentations shall be thirty (30) days.
If during the Review Period, Sponsor notifies Institution or Principal Investigator in writing that: (i) it desires patent applications
to be filed on any inventions disclosed or contained in the disclosures, Institution or Principal Investigator will defer Publication
for a period not to exceed sixty (60) days, to permit Sponsor to file any desired patent applications; and (ii) if the Publication
contains Sponsor’s Confidential Information as defined in Section 3 and Sponsor requests Institution or Principal Investigator
in writing to delete such Sponsor’s Confidential Information, the Institution and Principal Investigator agree to delete
such Sponsor’s Confidential Information only to the extent such deletion does not preclude the complete and accurate presentation
and interpretation of the Study results.

 

9.2.
The Parties agree that this Study is a multi-center clinical trial. Therefore, Institution and Principal Investigator agree that
the first Publication of the results of the Study shall be made in conjunction with the presentation of a joint multi-center Publication
of the Study results with the Principal Investigators from all sites contributing Data, analyses, and comments. However, Institution
or Principal Investigator may publish the Data and Study results individually in accordance with this Section 9 upon first occurrence
of one of the following: (i) multi-center Publication is published; (ii) no multicenter publication is submitted within twelve
(12) months after conclusion, abandonment, or termination of the Study at all sites; or (iii) Sponsor confirms in writing there
will be no multi-center Publication.

 

9.3.
If no multi-center Publication occurs within twelve (12) months of the completion of the Study at all sites, upon request by Institution
or Principal Investigator, Sponsor will provide such Institution or Principal Investigator access to the aggregate Data from all
Study sites.

 

9.4.
If Principal Investigator, is identified to participate in the multi-center Publication: (i) Principal Investigator will have
the opportunity to review the aggregate multi-center Data, upon request; and (ii) consistent with the International Committee
of Medical Journal Editors (ICMJE) regulations, Principal Investigator will have adequate opportunity to review and provide input
on any abstract or manuscript prior to its submission for Publication. Principal Investigator also retains the right to decline
to be an author on any Publication.

 

    	 	 	 

    	 

    

 

10.
Use of Name

 

10.1.
Neither Institution nor Principal Investigator nor CRO may use the name, trademark, logo, symbol, or other image or trade name
of any other party or their employees and agents in any advertisement, promotion, or other form of publicity or news release or
that in any way implies endorsement without the prior written consent of an authorized representative of the other party whose
name is being used. Such approval will not be unreasonably withheld.

 

10.2.
Institution and Sponsor understand that the amount of any payment made hereunder may be disclosed and made public by the other
party as required by law or regulation, including the Patient Protection and Affordable Care Act of 2010, provided that the disclosure
clearly designates the payment as having been made to Institution for research and not to the physician.

 

10.3.
Institution and Principal Investigator may acknowledge the Sponsor’s support, including but not limited to financial support
as may be required by academic journals, professional societies, funding agencies, and applicable regulations. Notwithstanding
anything to the contrary in this Agreement, Institution may publicly post information about the Study on Institution’s clinical
trials directory/website. Additionally, notwithstanding anything herein to the contrary, Institution shall have the right to post
Sponsor’s and/or CRO’s names, the Study title, and the Study period, and funding amount, on Institution publicly accessible
lists of research conducted by the Institution.

 

11.
Indemnification and Limitation of Liability

 

11.1
Sponsor’s indemnification obligations are outlined in a separate Letter of Indemnification, attached hereto as Exhibit
D.

 

11.2.
CRO expressly disclaims any liability in connection with the Study Drug or Study Device, including any liability for any claim
arising out of a condition caused by or allegedly caused by any Study procedures associated with such product except to the extent
that such liability is caused by the negligence, willful misconduct or breach of this Agreement by CRO.

 

11.3.
Institution and Principal Investigator shall have no obligation to indemnify CRO and CRO shall have no obligation to indemnify
Institution.

 

12.
Subject Injury

 

Sponsor’s
subject injury obligations are outlined in Exhibit D.

 

13.
Insurance

 

13.1.
Institution shall, at its sole cost and expense maintain a policy or program of insurance or self- insurance at the level of at
least $1,000,000 per occurrence (or per claim) and $3,000,000 annual aggregate to support its obligations assumed in this Agreement.
However, if Institution is a public entity entitled to governmental immunity protections under applicable state law, then Institution
may provide liability coverage in accordance with any limitations associated with the applicable law.

 

    	 	 	 

    	 

    

 

13.2.
Principal Investigator shall, at its sole cost and expense maintain a policy or program of insurance or self- insurance at the
level of at least $1,000,000 per occurrence (or per claim) and $3,000,000 annual aggregate to support its obligations assumed
in this Agreement.

 

13.2
CRO shall maintain an insurance policy or a program of self-insurance at levels sufficient to support its obligations assumed
herein.

 

13.4.
Upon written request, any Party will provide evidence of its insurance or self-insurance acceptable to another Party. Any Party
will provide the other Parties with written notice of material change in its coverage which would affect such Party’s ability
to meet its obligations under this Agreement. A Party’s inability to meet its insurance obligation constitutes material
breach of this Agreement.

 

14.
Term and Termination

 

14.1.
This term of this Agreement shall commence upon the Effective Date and terminate upon the completion of the Parties’ Study-related
activities under the Agreement, unless terminated early as further described in this Section.

 

14.2.
CRO has the right to terminate this Agreement upon thirty (30) days prior written notice to the Institution and Principal Investigator.
This Agreement may be terminated immediately at any time for any reason by the Institution, Principal Investigator or CRO when,
in their judgment or that of the Institution’s IRB, Scientific Review Committee, if applicable, or the Food and Drug Administration,
it is determined to be inappropriate, impractical, or inadvisable to continue, in order to protect the Study subjects’ rights,
welfare, and safety, or the IRB otherwise disapproves the Study. If for any reason Principal Investigator becomes unavailable
to direct the performance of the work under this Agreement, Institution shall promptly notify CRO. If the Parties are unable to
identify a mutually acceptable successor, this Agreement may be terminated by either Party upon thirty (30) days written notice.

 

14.3.
Notwithstanding the above a Party may, in addition to any other available remedies:

 

	 	a)	immediately
    terminate this Agreement upon the other Party’s material failure to adhere to the Protocol, except for deviation required
    to protect the rights, safety, and welfare of Study subjects; and/or
	 	 	 
	 	b)	terminate this Agreement
    upon the other Party’s material default or breach of this Agreement, provided that the defaulting/breaching Party fails
    to remedy such material default, breach, or failure to adhere to the Protocol within thirty (30) business days after written
    notice thereof.

 

14.4.
In addition to the above, this Agreement may be terminated by Institution or Principal Investigator in the event of a material
default or breach of this Agreement by CRO, or by CRO in the event of a material breach of this Agreement by Institution or Principal
Investigator, provided that the defaulting/breaching party fails to remedy such material default or breach within thirty (30)
business days after written notice thereof.

 

14.5.
In the event that this Agreement is terminated prior to completion of the Study, for any reason, Institution and Principal Investigator
shall:

 

	 	a)	notify
    the IRB that the Study has been terminated;
	 	 	 
	 	b)	cease enrolling
    subjects in the Study;

 

    	 	 	 

    	 

    

 

	 	c)	cease
    treating Study subjects under the Protocol as directed by CRO to the extent medically permissible and appropriate;
	 	 	 
	 	d)	terminate, as soon
    as practicable, all other Study activities; and
	 	 	 
	 	e)	furnish to CRO any
    required final report for the Study in the form reasonably acceptable to CRO.

 

Promptly
following any such termination, Institution and Principal Investigator will provide to CRO copies of Data collected pursuant
to the Study Protocol. Upon Sponsor’s or CRO’s written request, Institution and Principal Investigator shall
provide to the requesting party all Sponsor’s Confidential Information provided under this Agreement provided, however,
that Institution and Principal Investigator may each retain one (1) copy of Confidential Information for record keeping
purposes, monitoring its obligations, and exercising its rights hereunder, subject to Institution’s and Principal
Investigator’s ongoing compliance with the confidentiality and non-use obligations set forth in this
Agreement.

 

14.6.
If this Study is terminated early by any Party, the Institution shall be reimbursed for all work completed, on a pro rata basis,
and reasonable costs of bringing the Study to termination incurred through the date of termination, and for non-cancelable commitments
properly incurred through that date. Upon receipt of notice of termination, Institution will use reasonable efforts to reduce
or eliminate further costs and expenses and will cooperate with CRO to provide for an orderly wind-down of the Study.

 

14.7.
Subsections 1.4, 1.6, and 14.6, and Sections 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 (and the attached Letter of Indemnification), 12,
13, 15, 19 and 23, shall survive any termination or expiration of this Agreement, except that Section 3 shall survive for the
period stated in Section 3.1. Any provision of this Agreement that by its nature and intent remains valid after termination will
survive termination.

 

15.
Subject Material

 

15.1.
Subject Material means any biologic material of human origin including, without limitation, tissues, blood, plasma, urine, spinal
fluid, or other fluids derived from the Study subjects in accordance with and pursuant to the Protocol (“Subject Material”).

 

15.2.
Institution and Principal Investigator agree to make the Subject Material available to the Sponsor in accordance with the Protocol
for the purposes of the Study. The Subject Material may be used by the Sponsor, central lab, or other contracted party only as
allowed by the Study subject’s informed consent form or pertinent institutional review board(s). Sponsor’s use of
Subject Materials, other than as allowed by the Study subject’s informed consent form, will require additional IRB review
and approval.

 

16.
Subcontract

 

If
applicable, Institution and Principal Investigator have the right to subcontract to other sites to conduct the Study in accordance
with the Protocol with terms consistent with this Agreement with written approval of the Sponsor, which approval shall not be
unreasonably withheld. If Institution or Principal Investigator subcontracts any Study related duties, Institution and Principal
Investigator shall contract with such subcontractors incorporating terms substantially similar to the terms herein. Such subcontracts
may be provided to the CRO upon written request.

 

    	 	 	 

    	 

    

 

The
Parties acknowledge and agree that the Sponsor and each of its affiliates is a third party beneficiary to this Agreement.

 

17.
Notices

 

Any
notice, authorization, approval, consent or other communication will be in writing and deemed given:

 

	 	a)	Upon
    delivery in person; 
	 	 	 
	 	b)	Upon delivery by
    courier;
	 	 	 
	 	c)	Upon delivery date
    by a nationally-recognized overnight delivery service such as FedEx.

 

If
to CRO:

 

Cancer
Insight, LLC

Attn:
Steven White

Chief
Operating Officer

110
E. Houston St., Floor 7

San
Antonio, TX 78205

210-884-0810

swhite@cancerinsight.com

 

If
to Sponsor:

 

820
Heinz Avenue

Berkeley,
CA, 94710

Tel:
1-888-485-6340

Fax:
424-245-3719

 

If
to Institution:

 

St.
Joseph Heritage Healthcare

200
Center Street Promenade, Suite 800

Anaheim,
California 92805

Attention:
Clinical Trials & Research

 

If
to Principal Investigator:

 

St.
Joseph Heritage Healthcare

3555
Round Barn Circle Santa Rosa, CA 95403

Attention:
Clinical Trials & Research, Dr. Jarrod Holmes

 

    	 	 	 

    	 

    

 

18.
Independent Contractor

 

It
is mutually understood and agreed that the relationship among Institution, Principal Investigator and CRO is that of independent
contractors. No party shall represent itself as the agent, employee, partner, joint venturer, or servant of the others. Except
as specifically set forth herein, no party shall have nor exercise any control or direction over the methods by which another
party performs work or obligations under this Agreement. Further, nothing in this Agreement is intended to create any partnership,
joint ventures, lease, or equity relationship, expressly or by implication, among those parties.

 

19.
Clinical Trial Registry

 

Prior
to enrollment of the first subject in the Study, Sponsor will register the Study on www.clinicaltrials.gov in accordance with
the requirements of the International Committee of Medical Journal Editors (ICMJE) and Public Law 110-85. Results of this Study
will be reported in compliance with applicable laws.

 

20.
Non-Referral/Anti-Corruption Language

 

20.1.
Institution, Principal Investigator and CRO, on behalf of Sponsor, agree that it is not their intent under this Agreement to induce
or encourage the unlawful referral of subjects or business among the Parties, and there shall not be any requirement under this
Agreement that those parties, their employees or affiliates, including their medical staff, engage in any unlawful referral of
subjects to, or order or purchase products or services from, one of those parties.

 

20.2.
Institution, Principal Investigator and CRO, on behalf of Sponsor, agree that their employees, who are involved in the conduct
of the Study, will not offer, pay, request or accept any bribe, inducement, kickback or facilitation payment, and shall not make
or cause another to make any offer or payment to any individual or entity for the purpose of influencing a decision for the benefit
of one of those parties.

 

21.
Force Majeure

 

If
any Party hereto shall be delayed or hindered in, or prevented from, the performance of any act required hereunder for any reason
beyond such Party’s direct control, including but not limited to, strike, lockouts, labor troubles, governmental or judicial
actions or orders, riots, insurrections, war, acts of God, inclement weather, or other reason beyond the Party’s control
(a “Disability”) then such Party’s performance shall be excused for the period of the Disability. Any Study
timelines affected by a Disability shall be extended for a period equal to the delay and any affected Budget shall be adjusted
to account for cost increases or decreases resulting from the Disability. The Party affected by the Disability shall notify the
other Parties of such Disability as provided for herein.

 

22.
Counterparts

 

This
Agreement may be executed in any number of counterparts, each of which shall be an original and all of which together shall constitute
one and the same document, and is binding on all Parties notwithstanding that each of the Parties may have signed different counterparts.
Facsimiles or scanned copies of signatures or electronic images of signatures shall be considered original signature unless prohibited
by applicable law.

 

    	 	 	 

    	 

    

 

23.
Debarment

 

The
Institution and Principal Investigator each certifies that to its/his/her knowledge neither it/he/she, nor any of its/his/her
employees, agents or other persons performing the Study under its/his/her direction, is currently debarred, suspended, or excluded
under the Federal Food, Drug and Cosmetic Act, as amended, or disqualified under the provisions of 21 CFR §312.70. In the
event that the Principal Investigator or any Study personnel becomes debarred or disqualified during the term of this Agreement
or within 1 year after termination of the Study, the Institution and Principal Investigator agree to promptly notify CRO after
learning of such event. Institution and Principal Investigator each certifies that it/he/she is not excluded from a federal health
care program, including Medicare and Medicaid. In the event an Institution or Principal Investigator becomes excluded during the
term of this Agreement or within 1 year after termination of the Study, the Institution or Principal Investigator agrees to promptly
notify CRO after learning of such event.

 

24.
Institution Compliance Program

 

The
Parties acknowledge that Institution maintains a corporate compliance program (“Program”). This Program is intended
to prevent compliance violations and to promote education related to fraud, abuse, false claims including but not limited to the
Deficit Reduction Act provisions, excess private benefit, and inappropriate referrals. This Program requires, and the Parties
hereby agree, that any regulatory compliance concerns regarding any Institution compliance violations be promptly reported either
to an appropriate Institution manager or through the Institution’s Compliance Line at 1-866-913-0275.

 

25.
Tax Exempt Status

 

The
Parties acknowledge that Institution is entering into this Agreement with tax-exempt status. In the event it becomes necessary
to amend the Agreement in order for Institution to comply with its tax- exempt bond obligations and covenants, to maintain its
tax-exempt status, or to qualify for tax-exempt financing, the Parties agree to enter into good faith negotiations to amend this
Agreement for the purpose of allowing Institution to continue to comply with its tax-exempt and bond financing obligations under
the United States Treasury laws and regulations. If, however, after such negotiations and subsequent amendment to this Agreement,
Institution’s bond counsel or accountants believe that this Agreement continues to threaten Institution’s tax-exempt
status or causes Institution to be out of compliance with its bond obligations and/or covenants, or if the Parties cannot agree
to an amendment within thirty (30) days of initiation of such negotiations, then Institution may terminate this Agreement upon
thirty (30) days prior written notice to the other Parties. Institution represents that, to the best of its knowledge, Institution’s
entry into this Agreement and conduct of the Study does not jeopardize Institution’s tax-exempt status.

 

26.
Independent Review

 

Institution
and Principal Investigator each hereby represents that it/he/she has had an opportunity to review this Agreement and have this
Agreement reviewed by its/his/her counsel. Principal Investigator recognizes and agrees that counsel for Institution does not
represent the Principal Investigator in this matter.

 

27.
Choice of Law -Intentionally omitted

 

    	 	 	 

    	 

    

 

25.
Entire Agreement

 

Section
and clause headings are used herein solely for convenience of reference and are not intended as substantive parts of the
Parties’ agreement. This Agreement incorporates the Exhibits referenced herein. This written Agreement constitutes the
entire agreement among the Parties concerning the subject matter, and supersedes all other or prior agreements or
understandings, whether written or oral, with respect to that subject matter. Any changes made to the terms, conditions or
amounts cited in this Agreement require the written approval of each Party’s authorized representative. The waiver by
any party of a violation of any provision of this Agreement shall not operate as or be construed to be, a waiver of any
subsequent breach of the same or other provision hereof. In the event any provision of the Agreement is held to be
unenforceable for any reason, the unenforceability hereof shall not affect the remainder of this Agreement, which shall
remain in full force and effect and enforceable in accordance with its terms. Furthermore, it is the parties’ intent
that any unenforceable provision be construed and limited by any court that considers the matter so as to render it
reasonable and enforceable.

 

The
authorized representatives of the Parties have signed this Agreement as set forth below.

 

	St. Joseph Heritage Healthcare	 	Cancer Insight, LLC
	 	 	 	 	 
	By:		 	By:	
	 	 	 	 	 
	Name:	John Bennett	 	Name:	Steven White
	 	 	 	 	 
	Title:	Chief Administrative
    Officer	 	Title:	COO
	 	 	 	 	 
	Date:	Jan 24, 2018	 	Date:	1/26/2018

 

	Jarrod Holmes, M.D.	 
	 	 	 
	By:		 
	 	 	 
	Name:	Jarrod Holmes, M.D.	 
	 	 	 
	Title:	Principal Investigator	 
	 	 	 
	Date:	Jan 25, 2018	 

 

    	 	 	 

    	 

    

 

EXHIBIT
A

PROTOCOL

 

See
attached and incorporated master Protocol, which is identified as Protocol BRI-ROL-001, and amendments thereto.

 

    	 	 	 

    	 

    

 

EXHIBIT
B

BUDGET

 

	A.	This
    Budget has been negotiated at fair and reasonable value. Institution has not been influenced to participate in this Study
    based on financial or other inducements from Sponsor. The compensation may be used at the discretion of Institution to offset
    the costs of the Study. For Study subject visit and Study conduct reimbursements, an item listed herein will be considered
    payable upon Institution’s complete and accurate data entry into the applicable electronic data capture system (EDC)
    of all assessments associated with that visit in the EDC.
	 	 
	B.	Sponsor will not
    be liable for any payment in excess of the fees and costs provided herein except upon Sponsor’s prior written agreement.
    Institution may submit to Sponsor a revised budget requesting additional funds at such time as expenses may reasonably be
    projected to exceed the fees and costs provided herein.
	 	 
	C.	The compensation
    per Study subject will be earned by Institution and made payable by Sponsor as follows:

 

	 	i.	 	$2,270.00
    will be paid upon completion of the baseline visit, as defined by the Protocol;
	 	 	 	 
	 	ii.	 	$2,070.00
    will be paid upon completion of Cycle One, as defined by the Protocol;
	 	 	 	 
	 	iii.	 	$1,940.00
    will be paid upon completion of Cycle Two, as defined by the Protocol;
	 	 	 	 
	 	iv.	 	$1,940.00
    will be paid upon completion of Cycle Three, as defined by the Protocol;
	 	 	 	 
	 	v.	 	$1,940.00
    will be paid upon completion of Cycle Four, as defined by the Protocol;
	 	 	 	 
	 	vi.	 	$2,255.00
    will be paid upon completion of Cycle Five, as defined by the Protocol;
	 	 	 	 
	 	vii.	 	$1,940.00
    will be paid upon completion of Cycle Six, as defined by the Protocol;
	 	 	 	 
	 	viii.	 	$1,940.00
    will be paid upon completion of Cycle Seven, as defined by the Protocol;
	 	 	 	 
	 	ix.	 	$1,940.00
    will be paid upon completion of Cycle Eight, as defined by the Protocol;
	 	 	 	 
	 	x.	 	$2,255.00
    will be paid upon completion of Cycle Nine, as defined by the Protocol;
	 	 	 	 
	 	xi.	 	$1,940.00
    will be paid upon completion of Cycle Ten, as defined by the Protocol;
	 	 	 	 
	 	xii.	 	$1,940.00
    will be paid upon completion of Cycle Eleven, as defined by the Protocol;
	 	 	 	 
	 	xiii.	 	$1,940.00
    will be paid upon completion of Cycle Twelve, as defined by the Protocol;
	 	 	 	 
	 	xiv.	 	$2,255.00
    will be paid upon completion of Cycle Thirteen, as defined by the Protocol;
	 	 	 	 
	 	xv.	 	$1,940.00
    will be paid upon completion of Cycle Fourteen, as defined by the Protocol;

 

    	 	 	 

    	 

    

 

	 	xvi.	 	$1,940.00 will be
    paid upon completion of Cycle Fifteen, as defined by the Protocol;
	 	 	 	 
	 	xvii.	 	$1,940.00 will be
    paid upon completion of Cycle Sixteen, as defined by the Protocol; 
	 	 	 	 
	 	xviii.	 	 $2,255.00 will be paid upon completion of Cycle
    Seventeen, as defined by the Protocol;
	 	 	 	 
	 	xix.	 	$2,155.00 will be
    paid upon completion of the end of treatment visit, as defined by the Protocol.
	 	 	 	 
	 	xx.	 	$1,490.00
    will be     paid upon completion of the final assessment follow-up visit, as defined by the Protocol.

 

	D.	Start-up
    funding will be provided in the amount of $8,000.00 and payable upon execution of the Agreement, which may be used at the
    discretion of Institution to offset the costs of the Study.
	 	 
	E.	Where Institution
    utilizes Western IRB (“WIRB”) as their central IRB, Cancer Insight will pay for WIRB costs directly and Institution
    may direct WIRB to invoice Cancer Insight directly.
	 	 
	F.	Annual maintenance
    funding will be provided in the amount of $750.00, which may be used at the discretion of Institution to offset the costs
    of the Study. This amount shall be due beginning in the second year of the Study and shall continue until completion of the
    Study. The annual term shall be determined by the Effective Date of the Agreement.
	 	 
	G.	$500.00 shall be
    paid for each protocol amendment submitted to Institutional IRB or to WIRB.
	 	 
	H.	$1,500.00 shall
    be paid for the HRPP Institutional Oversight Fee.
	 	 
	I.	$500.00 shall be
    paid annually for the HRPP Institutional Oversight Fee. This amount shall be due beginning in the second year of the Study
    and shall continue until completion of the Study. The annual term shall be determined by the Effective Date of the Agreement.
	 	 
	J.	$250.00 shall be
    paid for each SAE report completed.
	 	 
	K.	$25.00 shall be
    paid for each IND safety report completed.
	 	 
	L.	Cardiac Safety monitoring
    shall be invoiced as required per the Protocol:

 

	 	i.	 	$550.00
    for echocardiogram per occurrence;
	 	 	 	 
	 	ii.	 	$2,191.00 for multigated
    acquisition (MUGA) scan per occurrence;
	 	 	 	 
	 	iii.	 	$44.00 for cardiac
    troponin test per occurrence;
	 	 	 	 
	 	iv.	 	$130.00 for electrocardiogram
    (ECG) per occurrence;
	 	 	 	 
	 	v.	 	$151.00 for NT-proBNP
    and Troponon (cTn) per occurrence.

 

    	 	 	 

    	 

    

 

	M.	Imaging
    scans shall be paid at the rates identified below. Such costs shall only be applicable to imaging scans that are considered
    to be outside the standard of care windows. If imaging scans are performed outside the Study subject’s standard of care
    and repeated at the baseline evaluation for research purposes only, such imaging scans shall be invoiced to Sponsor.

 

	 	i.	 	$2,227.00
    for CT Chest with contrast imaging;
	 	 	 	 
	 	ii.	 	$135.00 for RECIST
    reads;
	 	 	 	 
	 	iii.	 	$2,087.00 for CT
    Abdominal/Pelvis with contrast imaging.

 

	N.	Serology
    testing, as required by the Protocol, shall be paid at the rates identified below.

 

	 	i.	 	$60.00
    for HIV Screen;
	 	 	 	 
	 	ii.	 	$90.00 for Hepatitis
    B Screen;
	 	 	 	 
	 	iii.	 	$40.00 for Hepatitis
    C Virus Antibody;
	 	 	 	 
	 	iv.	 	$45.00 for C Carcinoembryonic
    antigen;
	 	 	 	 
	 	v.	 	$50.00 for Cancer
    Antigen 27.29;
	 	 	 	 
	 	vi.	 	$50.00 for Cancer
    Antigen 15-3;

 

	O.	Sponsor
    will provide pembrolizumab (KEYTRUDA®, anti-PD-1) and ipilimumab (YERVOY®, anti-CTLA-4), as applicable. Ipilimumab
    treatment is limited to four doses. For pembrolizumab, dosing may continue until disease progression, unacceptable toxicity,
    and/or up to twenty-four (24) months in Study subjects without disease progression.
	 	 
	P.	Sponsor will provide
    Interferon-Alpha, BriaVax, DTH (BriaTest), Anergy tests (Candin), and cyclophosphamide Study drugs.
	 	 
	Q.	In the event any
    Protocol-required study drugs are provided by Institution through their pharmacy or other means, the cost of such shall be
    invoiceable by Institution and paid by Sponsor.

 

    	 	 	 

    	 

    

 

	R.	Invoicing
    shall be conducted no more frequently than monthly. Invoices shall be sent to Cancer Insight. In the event that such method
    of delivery is rendered impossible or impractical, invoices may be sent to Cancer Insight via mail to:

 

Cancer
Insight, LLC

110
East Houston Street, Floor 7

San
Antonio, Texas 78205

 

	S.	Payments
    will be sent no later than thirty (30) days from receipt and approval of invoices. Payments will be issued via electronic
    funds transfer whenever possible and under the following instructions:

 

Bank
Name: The Bank of New York Mellon

Account
Number: 0780158

Routing
Number: 043000261

Emails
to jan.nielsen@stjoe.org and kim.smith@stjoe.org

 

	T.	In the
    event that such method of payment is rendered impossible or impractical, payments will be issued via check and mailed to the
    address included on the associated invoice.

 

    	 	 	 

    	 

    

 

EXHIBIT
C

ADMINISTRATIVE
AND STUDY POINTS OF CONTACT

 

CRO
Clinical Department Point of Contact:

 

Karen
Arrington

karrington@cancerinsight.com

 

CRO
Regulatory Department Point of Contact:

 

Cancer
Insight Regulatory

regulatory@cancerinsight.com

 

CRO
Administrative and Billing Department Point of Contact:

 

Steven
White

swhite@cancerinsight.com

 

    	 	 	 

    	 

    

 

EXHIBIT
D

INSTITUTION
LETTER OF INDEMNIFICATION (LOI)/SUBJECT INJURY

 

INSTITUTION:
St. Joseph Heritage Healthcare

 

TITLE
OF CLINICAL TRIAL: “A Phase I/IIa Rollover Study of the Whole-Cell Vaccine BriaVaxTM in Metastatic or Locally Recurrent
Breast Cancer Patients in Combination with Ipilimumab or Pembrolizumab”

 

CRO:
Cancer Insight, LLC

 

STUDY
NUMBER: BRI-ROL-001

 

	1)	Institution
    has entered into the Agreement with CRO to participate in the above sponsored Study. CRO has been engaged by BriaCell Therapeutics
    (the “Sponsor”) to arrange and administer this BriaCell Therapeutics sponsored multi-center clinical trial.
	 	 
	2)	Sponsor has delegated
    to CRO responsibility for the management and monitoring of this Study. Sponsor has further authorized CRO to bind Sponsor
    to its obligations within the Clinical Trial Agreement for this Study executed among CRO, Institution and Principal Investigator.
    Sponsor accepts responsibility for its obligations contained in the Agreement.
	 	 
	3)	Institution agrees
    to participate by allowing the Study to be undertaken utilizing such facilities, personnel and equipment as Institution may
    reasonably need for its conduct of the Study.
	 	 
	4)	In consideration
    of such participation by Institution, and subject to paragraph 5 below, the Sponsor shall defend, indemnify, and hold harmless
    the Institution and its medical affiliates and affiliated hospitals, and each of their trustees, officers, directors, governing
    bodies, subsidiaries, affiliates, investigators, employees, IRB members, agents, successors, heirs and assigns (collectively
    referred to as “Institution’s Indemnitees”), from and against any third party claims, loss, damage, cost
    and expense of claims (including reasonable attorney’s fees) and suits alleged to be caused by or arising from the Study
    or use of the Study Drug or Study Device under this Agreement or from the use of the Study results (“Claims”),
    regardless of the legal theory asserted.
	 	 
	5)	Sponsor shall have
    no obligation to provide such indemnification to the extent that such Claim is solely caused by Institution’s Indemnitee(s)’:
    (1) failure to adhere to and comply with all material and substantive specifications and directions set forth in the Protocol
    (except to the extent such deviation is reasonable to protect the rights, safety and welfare of the Study subjects); (2) failure
    to comply with all applicable laws and regulations in the performance of the Study; or (3) if such claim is directly caused
    by the negligent acts or omissions of Institution’s Indemnitees(s).
	 	 
	6)	Subject to the limits
    and without waiving any immunities provided under applicable law (including constitutional provisions, statutes and case law)
    regarding the status, powers and authority of the Institution or the Institution’s principal(s), Institution shall indemnify,
    hold harmless and defend Sponsor, its directors, officers, employees and agents, (“Sponsor’s Indemnitees”)
    from and against only those third-party Claims to the extent directly attributable to Institution’s negligence in its
    conduct of the Study. Notwithstanding the above, Institution shall have no obligation to indemnify Sponsor for any other Claims
    (including, but not limited to, infringement or product liability Claims).

 

    	 	 	 

    	 

    

 

	7)	The
    indemnified party shall give notice to the indemnifying party promptly upon receipt of written notice of a Claim for which
    indemnification may be sought under this Agreement, provided, however, that failure to provide such notice shall not relieve
    indemnifying party of its indemnification obligations except to the extent that the indemnifying party’s ability to
    defend such Claim is materially, adversely affected by such failure. Indemnifying party shall not make any settlement admitting
    fault or incur any liability on the part of the indemnified party without indemnified party’s prior written consent,
    such consent not to be unreasonably withheld or delayed. The indemnified party shall cooperate with indemnifying party in
    all reasonable respects regarding the defense of any such Claim, at indemnifying party’s expense. The indemnified party
    shall be entitled to retain counsel of its choice at its own expense. In the event a Claim falls under this indemnification
    clause, in no event shall the indemnified party compromise, settle or otherwise admit any liability with respect to any Claim
    without the prior written consent of the indemnifying party, and such consent not to be unreasonably withheld or delayed.
	 	 
	8)	EXCEPT FOR THE PARTIES’
    OBLIGATIONS TO INDEMNIFY EACH OTHER AS STATED ABOVE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, CONSEQUENTIAL
    OR INCIDENTAL DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF THE SAME.
	 	 
	9)	If a Study subject
    suffers an adverse reaction, illness, or injury which, in the reasonable judgment of Institution, was directly caused by a
    Study Drug or Study Device or any properly performed procedures required by the Protocol, Sponsor shall reimburse for the
    reasonable and necessary costs of diagnosis and treatment of any Study subject injury, including hospitalization, but only
    to the extent such expenses are not attributable to: (i) Principal Investigator’s, Institution’s, or Study subject’s
    negligence or willful misconduct; or (ii) the natural progression of an underlying or pre-existing condition or events, unless
    exacerbated by participating in the Study.
	 	 
	10)	Sponsor shall, at
    its sole cost and expense, procure and maintain commercial general liability insurance, clinical trial insurance and products
    liability insurance or equivalent self-insurance, unless otherwise indicated in an attached work order, in amounts not less
    than $5,000,000.00 per occurrence and $5,000,000.00 annual aggregate. Such commercial general liability insurance, clinical
    trial insurance and products liability insurance or equivalent self-insurance shall provide contractual liability coverage
    for Sponsor’s indemnification obligations herein. The minimum amounts of insurance coverage required in this paragraph
    shall not be construed to create a limit to Sponsor’s liability with respect to its indemnification under this LOI and
    the Agreement executed with the CRO for this Study.
	 	 
	11)	Upon written request,
    Sponsor will provide evidence of its insurance policy or a program of self-insurance and will provide Institution with written
    notice of any material change in its coverage which would affect Sponsor’s ability to meet its obligations under this
    Agreement. Sponsor’s inability to meet its insurance obligation constitutes material breach of this LOI and the Agreement
    executed with the CRO for this Study.
	 	 
	12)	During the Study
    and for at least two (2) years following the completion of the Study at all sites, Sponsor shall promptly provide Institution
    and Principal Investigator with the written report of any findings, including Study results and any routine monitoring findings
    in site monitoring reports, and data safety monitoring committee reports including, but not limited to, data and safety analyses,
    and any Study information that may (i) affect the safety and welfare of current or former Study subjects, (ii) affect the
    willingness of Study Subjects to continue their participation in the Study, (iii) influence the conduct of the Study or (iv)
    alter the IRB’s approval of the Study. Institution and/or Principal Investigator will communicate findings to the IRB
    and Study subjects, as appropriate.

 

    	 	 	 

    	 

    

 

	13)	Except
    as permitted in Article 10.3 in the Agreement, neither Institution nor Sponsor may use the name, trademark, logo, symbol,
    or other image or trade name of any other party or their employees and agents in any advertisement, promotion, or other form
    of publicity or news release or that in any way implies endorsement without the prior written consent of an authorized representative
    of the other party whose name is being used. Such approval will not be unreasonably withheld. 

 

The
authorized representatives have signed this Letter of Indemnification as set forth below.

 

	St. Joseph Heritage Healthcare	 	BriaCell Therapeutics
	 	 	 	 	 
	By:		 	By:	
	 	 	 	 	 
	Name:	John Bennett	 	Name:	William V. Williams
	 	 	 	 	 
	Title:	Chief Administrative
    Officer	 	Title:	President and CEO
	 	 	 	 	 
	Date:	Jan 24, 2018	 	Date:	1/26/2018

 

    	 	 	 

    	 

    

 

EXHIBIT
E

PRINCIPAL
INVESTIGATOR LETTER OF INDEMNIFICATION (LOI)/SUBJECT INJURY

 

Principal
Investigator: Jarrod Holmes, M.D.

 

TITLE
OF CLINICAL TRIAL: “A Phase I/IIa Rollover Study of the Whole-Cell Vaccine BriaVaxTM in Metastatic or Locally Recurrent
Breast Cancer Patients in Combination with Ipilimumab or Pembrolizumab”

 

CRO:
Cancer Insight, LLC

 

STUDY
NUMBER: BRI-ROL-001

 

	1)	Principal
    Investigator has entered into the Agreement with CRO to participate in the above sponsored Study. CRO has been engaged by
    BriaCell Therapeutics (the “Sponsor”) to arrange and administer this BriaCell Therapeutics sponsored multi-center
    clinical trial.
	 	 
	2)	Sponsor has delegated
    to CRO responsibility for the management and monitoring of this Study. Sponsor has further authorized CRO to bind Sponsor
    to its obligations within the Clinical Trial Agreement for this Study executed among CRO, Institution and Principal Investigator.
    Sponsor accepts responsibility for its obligations contained in the Agreement.
	 	 
	3)	Principal Investigator
    agrees to participate by allowing the Study to be undertaken utilizing such facilities, personnel and equipment as Principal
    Investigator may reasonably need for its conduct of the Study.
	 	 
	4)	In consideration
    of such participation by Principal Investigator, and subject to paragraph 5 below, the Sponsor shall defend, indemnify, and
    hold harmless the Principal Investigator from and against any third party claims, loss, damage, cost and expense of claims
    (including reasonable attorney’s fees) and suits alleged to be caused by or arising from the Study or use of the Study
    Drug or Study Device under this Agreement or from the use of the Study results (“Claims”), regardless of the legal
    theory asserted.
	 	 
	5)	Sponsor shall have
    no obligation to provide such indemnification to the extent that such Claim is solely caused by Principal Investigator’s:
    (1) failure to adhere to and comply with all material and substantive specifications and directions set forth in the Protocol
    (except to the extent such deviation is reasonable to protect the rights, safety and welfare of the Study subjects); (2) failure
    to comply with all applicable laws and regulations in the performance of the Study; or (3) if such claim is directly caused
    by the negligent acts or omissions of the Principal Investigator.
	 	 
	6)	Subject to the limits
    and without waiving any immunities provided under applicable law (including constitutional provisions, statutes and case law)
    regarding the status, powers and authority of the Principal Investigator, Principal Investigator shall indemnify, hold harmless
    and defend Sponsor, its directors, officers, employees and agents, (“Sponsor’s Indemnitees”) from and against
    only those third-party Claims to the extent directly attributable to Principal Investigator’s negligence in his conduct
    of the Study. Notwithstanding the above, Principal Investigator shall have no obligation to indemnify Sponsor for any other
    Claims (including, but not limited to, infringement or product liability Claims).

 

    	 	 	 

    	 

    

 

	7)	The
    indemnified party shall give notice to the indemnifying party promptly upon receipt of written notice of a Claim for which
    indemnification may be sought under this Agreement, provided, however, that failure to provide such notice shall not relieve
    indemnifying party of its indemnification obligations except to the extent that the indemnifying party’s ability to
    defend such Claim is materially, adversely affected by such failure. Indemnifying party shall not make any settlement admitting
    fault or incur any liability on the part of the indemnified party without indemnified party’s prior written consent,
    such consent not to be unreasonably withheld or delayed. The indemnified party shall cooperate with indemnifying party in
    all reasonable respects regarding the defense of any such Claim, at indemnifying party’s expense. The indemnified party
    shall be entitled to retain counsel of its choice at its own expense. In the event a Claim falls under this indemnification
    clause, in no event shall the indemnified party compromise, settle or otherwise admit any liability with respect to any Claim
    without the prior written consent of the indemnifying party, and such consent not to be unreasonably withheld or delayed.
	 	 
	8)	EXCEPT FOR THE PARTIES’
    OBLIGATIONS TO INDEMNIFY EACH OTHER AS STATED ABOVE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, CONSEQUENTIAL
    OR INCIDENTAL DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF THE SAME.
	 	 
	9)	If a Study subject
    suffers an adverse reaction, illness, or injury which, in the reasonable judgment of Principal Investigator, was directly
    caused by a Study Drug or Study Device or any properly performed procedures required by the Protocol, Sponsor shall reimburse
    for the reasonable and necessary costs of diagnosis and treatment of any Study subject injury, including hospitalization,
    but only to the extent such expenses are not attributable to: (i) Principal Investigator’s, Institution’s, or
    Study subject’s negligence or willful misconduct; or (ii) the natural progression of an underlying or pre-existing condition
    or events, unless exacerbated by participating in the Study.
	 	 
	10)	Sponsor shall, at
    its sole cost and expense, procure and maintain commercial general liability insurance, clinical trial insurance and products
    liability insurance or equivalent self-insurance, unless otherwise indicated in an attached work order, in amounts not less
    than $5,000,000.00 per occurrence and $5,000,000.00 annual aggregate. Such commercial general liability insurance, clinical
    trial insurance and products liability insurance or equivalent self-insurance shall provide contractual liability coverage
    for Sponsor’s indemnification obligations herein. The minimum amounts of insurance coverage required in this paragraph
    shall not be construed to create a limit to Sponsor’s liability with respect to its indemnification under this LOI and
    the Clinical Trial Agreement executed with the CRO for this Study.
	 	 
	11)	Upon written request,
    Sponsor will provide evidence of its insurance policy or a program of self-insurance and will provide Principal Investigator
    with written notice of any material change in its coverage which would affect Sponsor’s ability to meet its obligations
    under this Agreement. Sponsor’s inability to meet its insurance obligation constitutes material breach of this LOI and
    the Agreement executed with the CRO for this Study.

 

    	 	 	 

    	 

    

 

	12)	During the Study and for at least two (2) years following the completion of the Study at all sites, Sponsor shall promptly provide Institution and Principal Investigator with the written report of any findings, including Study results and any routine monitoring findings in site monitoring reports, and data safety monitoring committee reports including, but not limited to, data and safety analyses, and any Study information that may (i) affect the safety and welfare of current or former Study subjects, (ii) affect the willingness of Study Subjects to continue their participation in the Study, (iii) influence the conduct of the Study or (iv) alter the IRB’s approval of the Study. Institution and/or Principal Investigator will communicate findings to the IRB and Study subjects, as appropriate.

 

	13)	Except as permitted
    in Article 10.3 in the Agreement, neither Principal Investigator nor Sponsor may use the name, trademark, logo, symbol, or
    other image or trade name of any other party or their employees and agents in any advertisement, promotion, or other form
    of publicity or news release or that in any way implies endorsement without the prior written consent of an authorized representative
    of the other party whose name is being used. Such approval will not be unreasonably withheld.

 

The
authorized representatives have signed this Letter of Indemnification as set forth below.

 

	Jarrod Holmes, M.D.	 	BriaCell Therapeutics
	 	 	 	 	 
	By:		 	By:	
	 	 	 	 	 
	Name:	Jarrod Holmes, M.D.	 	Name:	Willam V. Williams
	 	 	 	 	 
	Title:	Principal Investigator	 	Title:	President and CEO
	 	 	 	 	 
	Date:	Jan 25, 2018	 	Date:	1/26/2018

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]